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Abstract
EMILY ANNE COLBY: Methods for Population Pharmacokinetics and
Pharmacodynamics
(Under the direction of Dr. Eric Bair)
Current applications of cross validation have been unsuccessful at identifying co-
variate effects in the population Pharmacokinetic/Pharmacodynamic (PK/PD) setting
when other methods find a covariate effect may exist. Software that does population
PK/PD modeling has a nice feature of being able to do a post hoc step without any
major iterations to obtain Bayesian parameter estimates and hence predictions for sub-
jects that were not in the dataset that was used to fit the model. This work proposes
cross validation methods for longitudinal mixed effects models that are effective at
identifying covariate effects when they exist.
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Chapter 1
Introduction and Literature Review
1.1 Introduction
Cross validation has been used in various forms in the population pharmacokinetic
(PK) setting. With all the variations, there are two common uses of cross valida-
tion currently being used for population Pharmacokinetic/Pharmacodynamic (PK/PD)
modeling. Those are final model validation and model comparison.
For model comparison, cross validation has been unsuccessful at finding covariate
effects when other methods seem to imply that covariate effects exist (Zomorodi et al.,
1998), (Fiset et al., 1995). However, cross validation has been successful at identifying
models with major structural differences (Valodia et al., 2000).
It will be shown in Chapter 2 that when covariate effects are present in an underlying
population PK/PD model, a misspecification of failing to include a covariate effect may
not hurt the overall predictive performance of the model in the outcome variable or
concentration. Random effects in the pharmacokinetic parameters can make up for
the lack of the covariate. Therefore, cross validation metrics that involve the predicted
concentration errors will fail to identify a covariate effect. We instead propose using
the post hoc estimates of the random effects as metrics for identifying covariate effects
in population PK/PD models.
First, a review of the literature is presented. Then, the methods are proposed and
evaluated using simulated data examples and real data examples.
1.2 Literature Review
This chapter reviews the literature pertaining to population pharmacokinetics and
pharmacodynamics.
1.2.1 Background
Population pharmacokinetic and pharmacodynamic (PK/PD) modeling is the char-
acterization of the distribution of probable PK/PD outcomes (parameters, concentra-
tions, responses, etc.) in a population of interest. These models consist of fixed and
random effects. The fixed effects describe the relationship between explanatory vari-
ables such as age, body weight, gender, and pharmacokinetic outcomes. The random
effects quantify unexplained variation in PK/PD outcomes (FDA, 1999).
Population PK/PD modeling is useful for identifying influential covariates that may
warrant some action, such as changes in labeling, dose adjustment, contraindication,
and modification of design of future clinical trials. Quantification of unexplained vari-
ation in PK may be relevant to assessing safety risks and determining whether dose
individualization is desirable or necessary. It can answer questions like “Is it all right
to give everyone the same dose, regardless of body weight? If not, how should the doses
be scaled?” (FDA, 1999).
In some cases, population PK modeling is a de facto requirement. The FDA may
require that population PK modeling be performed for a new drug. Population analysis
of patient data may be used in lieu of some types of PK trials, e.g., renal impairment
or drug-drug interaction studies (FDA, 1999).
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There are two approaches to population modeling: the two-stage approach and non-
linear mixed effects (NLME) modeling (FDA, 1999). The two-stage approach consists of
fitting PK models for each individual separately, then summarizing the PK parameters
across individuals. Covariate relationships may be found by regressing the natural log
of the PK parameters with covariates of interest. The NLME approach differs in that
it fits one model across all individuals. This paper will focus on the NLME approach.
1.2.2 Structure of Population PK/PD Models
Population PK models are hierarchical (Davidian and Giltinan, 1995). There is a
model for the individual, a model for the population, and a model for the residual error.
The individual model consists of the curve of drug concentrations over time.
To explore the model for the individual, one must have a basic understanding of drug
pharmacokinetics. There are four basic phases of drug pharmacokinetics: Absorption,
Distribution, Metabolism, and Excretion (ADME). Typically a drug is given as an
injection (intravenous), an infusion, or extravascular dose (oral, sublingual, inhalation,
patch). Once the drug enters the body, it may undergo an absorptive phase prior to
being taken into the plasma. If it is injected as a bolus, this phase does not occur. Once
in plasma, the drug is distributed to various organs and tissues. It is often metabolised
by an organ such as the liver or kidney, then excreted in urine, feces, or by exhalation.
Drug concentration data can be modeled with compartmental modeling, which in-
volves curve fitting, or non-compartmental analysis (NCA). Non-compartmental analy-
sis consists of calculation of pharmacokinetic parameters based on the data alone, with
very few assumptions involved. Parameters such as Tmax, the time at which the max-
imum concentration, Cmax, occurs, and AUC, the area under the concentration-time
curve are calculated. The AUC is calculated using a trapezoidal method, where the
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concentration data points are connected with straight lines, and lines are drawn to the
x-axis (time) to get trapezoidal areas for each time segment. The sum of the trape-
zoidal areas approximates the AUC. Simple linear regression is used to estimate the
slope of the line in the elimination phase, referred to as lambdaZ, or rate of elimination
(Gabrielsson and Weiner, 2000). There are many variations on this method, including
ones that assume the decline in concentrations is log-linear (Gabrielsson and Weiner,
2000).
In population pharmacokinetic models, curve fitting is used to derive mean/population
pharmacokinetic parameters of interest as well as to predict corresponding concentra-
tion values for individual patients. The curve of the plasma concentrations over time is
sometimes modeled by a compartmental model, which assumes that the body is made
up of “compartments” through which the drug passes prior to being excreted. The
pharmacokinetic compartmental model is similar to a “black box” engineering model.
Each of the compartments is a “black box,” where a system of differential equations is
derived based on the law of conservation of mass. By the law of conservation of mass,
the change in the amount of drug versus time is equal to the sum of the contributing
mass flow rates for each compartment (Sandler, 1999). See Figure 1.1 for an example of
such a model. For example, the changes in drug amounts over time for a three compart-
ment pharmacokinetic model with extravascular (non-intravenous) administration can
be represented by the following differential equations. Note that there is an equation
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Figure 1.1: A three-compartment pharmacokinetic model
for each compartment.
dAa
dt
= −Ka · Aa
dA1
dt
= Ka · Aa − Cl · C − Cl2 · (C − C2)− Cl3 · (C − C3)
dA2
dt
= Cl2 · (C − C2)
dA3
dt
= Cl3 · (C − C3)
where Aa is the amount in the absorption compartment, and A1, A2, and A3 are
the amounts in the central and peripheral compartments, respectively. The rate of
absorption of the drug into the central compartment is denoted Ka. The flows of the
drug into and out of the peripheral compartments are denoted Cl2 and Cl3, and the
flow of drug out of the body is denoted Cl. The corresponding volumes associated with
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each compartments are V , V2, and V3, respectively. Then, we have the concentrations
C =
A1
V
C2 =
A2
V2
C3 =
A3
V3
The equation for C represents the model for the individual in the hierarchy of models.
However, one needs to account for unexplained variability. (Note: The above example
assumes the kinetics of drug transfer are first order. However, variations of such a
model that employ non-linear kinetics can also be accommodated.)
The model for the residual error accounts for overall uncertainty in the concen-
trations over time. It captures all variability not captured by the specified fixed and
random effects. The errors may weighted so that measurements with higher variabil-
ity are given less weight compared with measurements with smaller variability. For
example, under a constant CV percentage error model,
CObs = C · (1 + C)
where CObs is the observed concentration, C is the predicted concentration, and C is
the residual error. C is almost always assumed to follow a univariate normal distribu-
tion with mean 0 and variance σ2. With a constant CV percent error model, higher
concentration measurements (which tend to be more variable) are given less weight
(Gabrielsson and Weiner, 2000). Other options for weighting include
1. Additive (Uniform): CObs = C + C
2. Log-Additive (equivalent to fitting a model to the log of the observations): CObs =
C · exp(C), would reduce to an Additive error model if one were to take the log:
6
ln(CObs) = ln(C) + C
3. Power: CObs = C + C
power · C. Special case: Power=0.5 is Poisson weighting:
CObs = C + C
0.5 · C
4. Mixed is a combination of Proportional and Additive: CObs = C + C + C · C ·
CMixRatio
5. Custom
For a non-population model, the parameters Ka, V , Cl, V2, Cl2, V3, and Cl3 are
modeled with fixed effects only– that is, they are estimated separately for each indi-
vidual. For a population model, one estimates the population mean values, and the
amount each subject’s values deviate from the population means in a simultaneous fit
of all subject’s data. In a population model, the PK parameters can be modeled with
regression equations containing fixed effects, covariates, and random effects. The equa-
tions for the PK parameters represent the model for the population in the hierarchy of
models. For example,
Ka = θKa · exp(ηKa + ηKa,P1P1 + ηKa,P2P2)
V = (θV + dV dTrt · Trt) · exp(ηV )
V2 = (θV2 + dV2dFed · Fed) · exp(ηV2)
V3 = (θV3 + (W/W¯t)
dV3dWt) · exp(ηV3)
Cl = (θCl + dCldGene ·Gene) · exp(ηCl)
Cl2 = θCl2 · exp(ηCl2)
Cl3 = θCl3 · exp(ηCl3)
where θx denotes the fixed effect or typical value of a PK parameter x, and ηx denotes
a random effect for a PK parameter x. The distribution of PK parameters is generally
skewed to the right, and is often model with a log-normal distribution (this is why the
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random effects are often exponentiated in the equations for the PK parameters). The
vector of random effects is assumed to follow a multivariate normal distribution with
mean 0 and variance-covariance matrix Ω. Ω may be diagonal, full block, or block
diagonal.
Covariates such as Trt, an indicator that a specific drug was given, can be included.
In the example above, Fed and Gene are indicators that a subject was fed and that a
certain gene is present, and Wt is a continuous variable for the body weight of a subject.
(W¯ t represents the mean of Wt across all subjects.) The effects of the covariates on
the PK parameters are given by dV dTrt, dV2dFed, dV3dWt, and dCldGene.
Occasion covariates such as P1, an indicator for the first set of visits, and P2, an
indicator for the second set of visits, are typically included with random effects such as
ηKa,P1 and ηKa,P2 . They are usually assumed to be independent, normally distributed
with mean 0 and equal variance.
Hence, population pharmacokinetic models are non-linear mixed effects models.
The differential equations may or may not have a closed-form solution, and are solved
either analytically or numerically. The parameters are estimated using one of the
various algorithms available such as first order conditional estimation with interaction
(FOCEI) (Bonate, 2006).
1.2.3 Population PK/PD Modeling Procedure
Based on the FDA guidance for Population Pharmacokinetics (1999), population
PK modeling can be carried out in three, interwoven steps: Exploratory Analysis,
Model Development, and Model Validation (FDA, 1999).
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Exploratory Analysis
The exploratory analysis consists of plotting and summarizing the data in a tab-
ular format. Individual modeling of concentration data, via compartmental modeling
or non-compartmental analysis, may be performed to obtain initial estimates for the
population model. Linear regression of the natural log of the PK parameters to the
covariates of interest may be done as part of the exploratory analysis. Linear regression
may also be used to determine the structure of the PK model (for example, if clear-
ance changes with dose, one may consider a Michaelis-Menten model for clearance)
(Gabrielsson and Weiner, 2000).
A Michaelis-Menten model for clearance may have the form Cl = (Vmax/(Km +
C)) where Vmax (maximum metabolic rate) and Km (Michaelis Menten constant)
are parameters, and C is the predicted concentration. Drugs such as Ethanol exhibit
Michaelis-Menten pharmacokinetics. From inspection of the equation for clearance, one
can see that the Michaelis-Menten clearance decreases as the concentration increases.
This can happen when the metabolizing enzymes become saturated, making the process
of metabolism slower with an increase in drug concentration (Gabrielsson and Weiner,
2000).
Population Model Development
Model development consists of spelling out objectives, hypotheses, and assumptions,
followed by model building (FDA, 1999). The proposed model building procedure will
depend on the objectives, hypotheses, and assumptions. For example, if whether or
not a subject is fed is expected to have an effect on the PK, one will plan to include
a covariate for fed/fasted state prior to doing the model building and plan to test the
hypothesis that fed/fasted state has no effect on the PK during the model building
9
process.
Population Model Building
Model building consists of three steps: Base/Structural Model, Covariate Model,
and Covariance Model (FDA, 1999).
Base/Structural Model
The structure of the PK model is determined largely during the exploratory analysis,
where the concentrations are plotted on the log scale versus time. The number of
compartments may be determined by observing the number of distinct phases visible
in the plot (Gabrielsson and Weiner, 2000). For example, Figure 1.2 is a plot of the drug
concentration versus time for a drug that exhibits two compartment pharmacokinetics.
In Figure 1.2, the concentration increases from zero as the drug is absorbed, until it
reaches the maximum concentration, Cmax. After reaching Cmax, the drug concentration
in plasma decreases sharply at first if the distribution is rapid, then decreases again at a
different rate. The two distinct phases after Cmax are modeled with two compartments:
a central compartment and a peripheral compartment. However, the steeper decline
may represent elimination if distribution is slower than elimination.
Imagine having several curves like Figure 1.2 in a single plot, varying slightly from
one another, representing drug concentrations for several individuals (see Figure 2.5 for
an example). In that case, the base/structural population PK model would be a two
compartment model with random effects for the PK parameters Ka, V , Cl, V2, and
Cl2. A non-linear mixed effects model is generally used to predict average/population
PK values, and then the etas (random effects) are used to estimate how much each
10
Figure 1.2: Drug concentration versus time for a two-compartment model
individual deviates from the population PK value.
To obtain initial estimates for the fixed effects PK parameters in the base/structural
model, one may use traditional methods such as curve stripping (Gibaldi and Perrier,
1975). This method is built in to the WinNonlin Classic models and is performed
automatically when the defaults are accepted. One may also use non-compartmental
analysis (Gibaldi and Perrier, 1975) for obtaining initial estimates. Also, the Naive
Pooled method in Phoenix NLME (Pharsight) can be used to get rough estimates
for the fixed effects (essentially FOCEI with random effects parameters frozen to 0),
especially when the data are relatively sparse.
Once fixed effects initial estimates are found, one builds up to obtaining rough
estimates for the variances and covariances of the random effects. A method called
First Order (FO) can be used to accomplish this (Sheiner, Rosenberg and Melmon,
1972), as well as iterative two stage Expectation-Maximization (IT2S-EM) in Phoenix
NLME (Ette and Williams, 2004).
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Estimation Methods
The covariate selection, covariance structure selection, and final model are fitted
with an FOCEI method, QRPEM, or a Laplacian method. Two kinds of FOCEI, First
Order Conditional Estimation- Extended Least Squares (FOCE-ELS) and First Order
Conditional Estimation Lindstrom-Bates (FOCE L-B), are implemented in Phoenix
NLME. Of the FOCEI methods, the Lindstrom Bates method tends to run faster than
the ELS method. The Laplacian method is considered to be the most numerically
correct of all the methods, and can be used for things like Poisson regression or other
regression models where the likelihood function is specified by the user, though it
generally takes longer to run. See (Ette and Williams, 2004) for a description of these
methods. QRPEM was recently implemented in Phoenix NLME (in March of 2012)
and has been excellent at fitting the more complex models for this work (Leary and
Dunlavey, 2012).
Covariate Model
With the base/structural model determined, one can plot random effects versus co-
variates to determine whether covariates should be added. Then, one proceeds to the
covariate model building stage. Covariate model building may be carried out using like-
lihood ratio tests (LRTs) when candidate models are nested. There may be an inflated
type I error rate associated with the LRTs (Bertrand et al., 2009). Sometimes, the
stepwise procedure is used. One can also look at the relative standard error percent-
ages of the covariate effect estimates. If the relative standard error percentage is large,
there may not be enough data to support the covariate in the model. If the relative
standard error percentage is small (below 30), one may consider keeping the covariate
in the model. Once covariate modeling is complete, the inter-subject covariance model
12
is determined.
Covariance Model
The inter-subject covariance model is defined by the structure of the Ω matrix. Ran-
dom effects with low shrinkages (less than around 0.3) are kept in the model (Karlsson
and Savic, 2007) (Savic and Karlsson, 2007), otherwise, random effects may be removed.
For the random effects that are kept, the Ω matrix may be full block (all random effects
correlated), block diagonal (some random effects correlated, some independent of the
others), or diagonal (no random effects correlated). A scatter plot of the etas versus
the etas for the final covariate model may be used to help determine the structure of
Ω.
To obtain a robust estimate of the Ω matrix, one may use a non-parametric method.
One is built in to Phoenix NLME. It starts with a parametric solution, then performs
non-parametric iteration(s). If the estimate of the Ω matrix found using the non-
parametric method is vastly different from that of the parametric method, it may
indicate that one or more of the random effects has a bimodal distribution or some
other deviation from a normal distribution. This may mean that a covariate was left
out that should have been included (Davidian and Giltinan, 1995).
Model Validation
Once a final model is determined, model validation is done. Model validation may
be performed using bootstrapping or predictive check. Consider a dataset containing
concentration-time data for n subjects. Suppose one were to take a simple random
sample with replacement of size n, fit a model, and obtain estimates. Then, perform
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this x times, and summarize the model estimates across the x samples. This procedure
is known as bootstrapping (Efron and Tibshirani, 1986) for population PK. Histograms
of the bootstrapped model estimates may also be generated. It is known that the
estimates of the standard errors of the model estimates can be biased. To account for
this, boot-strapping is often employed to get better estimates of the variability. In many
cases, it is the only way to obtain estimates of the variability of the model estimates,
because the standard errors cannot always be calculated via matrix decomposition
(Yafune and Ishiguro, 1999).
Predictive check is used to generate a population of subjects based on the fitted
model, and then visually determine if this distribution provides good coverage of the
underlying data on which the model was based (Karlsson and Holford, 2008). Beginning
with a final model, the final model estimates are assumed to be correct. Then, based
on the model assumptions that C is normally distributed with mean 0 and variance
σ2, and η follows a multivariate normal distribution with mean 0 and variance Ω, new
concentration-time observations are simulated for x replicates of n subjects. If the
measurements are not taken at the same times for all subjects, similar times are binned
(using an algorithm such as the k-means clustering algorithm). For each time bin,
quantiles of the observed and simulated concentrations are calculated. A visual plot
of the observed data with bands for the observed and simulated quantiles is used to
determine whether the model fits the data.
1.2.4 Challenges in Population PK/PD Modeling
There are various challenges associated with population PK modeling. The struc-
tural model generally cannot be identified based on sparse data alone. In this case,
one may need meta-data which includes some rich data. Convergence is often difficult,
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resulting in having to set some parameters to a constant (or zero) or fitting a less
complex model. Covariate model building can be time consuming and lead to inflated
type I error rates (Wahlby, Jonsson and Karlsson, 2001). Estimates of precision of
parameters are often biased and require bootstrapping or other techniques. Depending
on model complexity, richness of data and other issues, it may take hours (or days) to
achieve convergence. Message Passing Interface (MPI) may be used to take advantage
of multiple processors on a single machine in Phoenix NLME. Also, a grid or cluster of
multiple computers may be used for parallel processing.
1.2.5 Smoothing Splines
A discussion of smoothing splines is given here because in Chapter 4 we will compare
population PK models to smoothing splines for prediction of concentrations. Suppose
we are given a set of response variables {yi}ni=1 and predictor variables {xi}ni=1 and we
wish to estimate each yi based on f(xi), where f is a function that minimizes
n∑
i=1
[yi − f(xi)]2 + λ
∫
{f ′′(t)}2 dt (1.1)
Any such f must be an element of the Sobolev space of functions with second derivatives
that are square integrable. The tuning parameter λ controls the tradeoff between
goodness of fit and smoothness. When λ = ∞, no second derivative is allowed for f ,
meaning that f must be linear and (4.2) reduces to the ordinary least squares criteria.
When λ = 0, then any f that interpolates the data will minimize (4.2).
It can be shown that (4.2) is minimized when f is a natural cubic spline with knots
at each xi (Hastie, Tibshirani and Friedman, 2008). Let x(1), x(2), . . . , x(n) be the order
statistics of the xi’s. Then a natural cubic spline f(x) with knots x1, x2, . . . , xn satisfies
the following properties:
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1. f(x) is a a piecewise cubic polynomial. In particular, f(x) is a cubic polynomial
on [x(1), x(2)], [x(2), x(3)], . . . , [x(n−1), x(n)].
2. f(x) and its first two derivatives are continuous on [x(1), x(n)].
3. f (j)(x(1)) = f
(j)(x(n)) = 0 for j = 2, 3. In other words, the second and third
derivatives of f are zero at the boundary knots, which implies that f is linear
outside the boundary knots.
See (Welham, 2009) or (Dierckx, 1995). For a complete description of smoothing splines
and methods for fitting spline models (including the choice of the tuning parameter λ),
see (Hastie, Tibshirani and Friedman, 2008).
1.2.6 Cross-Validation
A discussion of cross-validation is given here because in Chapters 2 and 3 we propose
new cross-validation methods for population PK/PD covariate model building. Cross-
validation is a method for evaluating the expected accuracy of a predictive model.
Suppose we have a response variable Y and a predictor variable X and we seek to
estimate Y based on X. Using the observed X’s and Y ’s we may estimate a function fˆ
such that our estimated value of Y (which we call Yˆ ) is equal to fˆ(X). Cross-validation
is an estimate of the expected loss function for estimating Y based on fˆ(X). If we use
squared error loss (as is conventional in population PK modeling), then cross-validation
is an estimate of E
[(
Y − fˆ(X)
)2]
.
A brief explanation of cross-validation is as follows: First, the data is divided into
K partitions of roughly equal size. For the kth partition, a model is fit to predict Y
based on X using the K − 1 other partitions of the data. (Note that the kth partition
is not used to fit the model.) Then the model is used to predict Y based on X for
the data in the kth partition. This process is repeated for k = 1, 2 . . . , K, and the K
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estimates of prediction error are combined. Formally, let fˆ−k be the estimated value of
f when the kth partition is removed, and suppose the indices of the observations in the
kth partition are contained in Kk. Then the cross-validation estimate of the expected
prediction error is equal to
1
n
k∑
i=1
∑
j∈Ki
(
yj − fˆ−i(xj)
)2
Here n denotes the number of observations in the data set. For a more detailed discus-
sion of cross-validation, see (Hastie, Tibshirani and Friedman, 2008).
1.2.7 Current Uses of Cross-Validation in Population PK/PD
As mentioned earlier, covariate model building may be carried out using likelihood
ratio tests (LRTs) when candidate models are nested. However, there may be an
inflated type I error rate associated with the LRTs (Bertrand et al., 2009). For model
comparison, cross validation has been unsuccessful at finding covariate effects when
other methods seem to imply that covariate effects exist (Zomorodi et al., 1998), (Fiset
et al., 1995). However, cross validation has been successful at identifying models with
major structural differences (Valodia et al., 2000).
Cross validation is not often done with population PK modeling (Brendel et al.,
2007). In one case (Bailey, Mora and Shafer, 1996), data was pooled across subjects
to fit a model as though the data were obtained from a single subject. Subjects were
removed, one at a time, and the accuracy of the predicted observations with subsets
of the data was assessed. The method we propose is different because it does not pool
the data across subjects prior to modeling, and we use it to compare candidate mod-
els rather than to assess accuracy of prediction. Another paper (Hooker et al., 2008)
describes removing a subject at a time to estimate model parameters, then predicting
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PK parameters using the covariate values for the subject that was removed and com-
paring those with the PK parameters obtained using the full data set, to evaluate the
final model and identify influential individuals. The method we propose is different in
that it uses a post-hoc step to calculate random effect values for the subject that is
removed, and instead of evaluating a final model or identifying influential individuals
we use cross validation to compare candidate models.
One article, (Ralph et al., 2006) calculates a prediction error for each subject in the
model parameters, and a paired t-test is done on the prediction error between a base
and full model to assess whether difference in imprecision of clearance between models
is significant. The prediction error is calculated as the difference in the individual and
population estimate divided by the individual estimate, times 100 percent, where the
individual estimate is obtained using cross validation. The full model is only found to
be correct with high levels of the covariate. This is fairly similar to the method we
propose, except the statistic is different and a t-test is not employed, thus making it
easier to find a covariate effect if there is one.
In (Zomorodi et al., 1998), cross validation is performed and weighted residuals
for subjects left out are used to compare a base and full model. Predictions obtained
for subjects left out may or may not have been based on the post hoc parameter
estimates (article not clear). The base model is found to be better with the cross
validation approach, but in other parts of paper the covariate is found to be significant.
Actual model development was performed using a likelihood based approach. Later in
this work, we explain why covariate effects go unidentified when the cross validation
prediction error in the y’s is used for comparing models in the population PK/PD
setting.
In (Mulla et al., 2003), (Kerbusch et al., 2001), and (Rajagopalan and Gastonguay,
2003), actual model development was performed using a likelihood based approach.
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Predictive performance of the final model is assessed using cross validation. In (Ker-
busch et al., 2001), “if model predictions based on partial dataset were in accordance
with predictions of full dataset, predictive ability of model was confirmed” (here authors
cited (Efron and Tibshirani, 1993)).
Covariate models are compared using cross validation in (Fiset et al., 1995). Cross
validation error in concentrations ((Obs - Pred)/Pred)*100 was used for comparing
covariate models. All models in the comparison had similar cross validation results.
Actual model development was performed using likelihood based approaches.
A poster presented in 2001 at PAGE by Ribbing (Ribbing and Jonsson, 2001) pro-
poses a method for cross validation, referred to as cross model validation (CMV). With
this method, cross validation is used with the objective function value (similar to log
likelihood function) to select a covariate model. A similar method is proposed in (Kat-
sube et al., 2011).
It may be that researchers were finding that cross validation as it is typically done
for population PK/PD modeling is not helpful for detecting covariates. In (Wahlby,
Jonsson and Karlsson, 2001), for the cross validation, one concentration data point for
each parameter, the point at which the parameter is most sensitive, was chosen based
on partial derivatives. In the cross-validation, the models showed similar predictive
ability with respect to both measures of the concentration prediction errors defined in
the article. It seems that even using the cross validation prediction error in the y’s at
the points that are most sensitive to the PK parameter with the covariate of interest
does not help to elucidate a covariate relationship when one appears to exist.
It will be shown in Chapter 2 that when covariate effects are present in an underlying
population PK/PD model, a misspecification of failing to include a covariate effect may
not hurt the overall predictive performance of the model in the outcome variable or
concentration. Random effects in the pharmacokinetic parameters can make up for
19
the lack of the covariate. Therefore, cross validation metrics that involve the predicted
concentration errors will fail to identify a covariate effect. We instead propose using
the post hoc estimates of the random effects as metrics for identifying covariate effects
in population PK/PD models.
1.2.8 Automated Covariate Selection in Population PK/PD
A commonly used method for automated covariate selection in population PK/PD
modeling is forward addition then backward elimination. It is often referred to as
“stepwise”, though it’s different from the stepwise procedure used in traditional linear
regression in that it does forward once, then backward once (Jonsson and Karlsson,
1998). Another method is GAM (Mandema, Verotta and Sheiner, 1992). A comparison
of these methods can be found in (Wahlby, Jonsson and Karlsson, 2002). Maitre first
proposed looking at the plots of the random effects versus the covariates to aid covariate
model selection (Maitre et al., 1991). It was found that tree based modeling with cross
validation to determine the tree size can help identify possible covariate models (Jonsson
and Karlsson, 1999), but it does not seem that the cross validation method described
involved re-fitting of the population model. This paper further explores the use of cross
validation for automated covariate selection, with cross validation in the post hoc etas
obtained from re-fitting population models.
1.3 Proposed Research
The following chapters will show why current uses of cross validation have failed to
detect covariate relationships when they seem to exist and propose new methods for
covariate model selection using cross validation. Finally, a comparison of mixed effect
spline models to population pharmacokinetic models will be made.
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Chapter 2
Cross validation for Longitudinal
Mixed Effects Models
2.1 Overview
Current applications of cross validation have been unsuccessful at identifying co-
variate effects in the population PK/PD setting when other methods find a covariate
effect may exist, due to the fact that the cross validation error used for covariate model
comparison was that of the y’s instead of the etas. Cross validation error in the y’s
is useful for identifying structural models but not for identifying covariate models in
the population PK/PD setting. Software that does population PK/PD modeling has a
nice feature of being able to do a post hoc step without any major iterations to obtain
Bayesian parameter estimates and hence predictions for subjects that were not in the
dataset that was used to fit the model. This article propose a cross validation method
for longitudinal mixed effects models that is effective at identifying covariate effects
when they exist, and two other methods for identifying a structural model.
2.2 Introduction
Cross validation has been used in various forms in the population pharmacokinetic
setting. With all the variations, there are two common uses of cross validation currently
being used for population PK/PD modeling. Those are final model validation and
model comparison.
For model comparison, cross validation has been unsuccessful at finding covariate
effects when other methods seem to imply that covariate effects exist (Zomorodi et al.,
1998), (Fiset et al., 1995). However, cross validation has been successful at identifying
models with major structural differences (Valodia et al., 2000). In these instances, cross
validation error in the y’s was used for model comparison. There are other methods
available to compare population pharmacokinetic/pharmacodynamic (PK/PD) models,
such as the likelihood ratio test (LRT), however there may be an inflated Type I error
rate associated with these methods in the population PK/PD setting (Bertrand et al.,
2009).
When covariate effects are present in an underlying population PK/PD model, a
misspecification of failing to include a covariate effect may not hurt the overall predictive
performance of the model in the outcome variable y or concentration. Random effects
in the pharmacokinetic parameters can make up for the lack of the covariate. Therefore,
cross validation metrics that involve the predicted outcome or concentration errors (y’s)
will often fail to identify a covariate effect.
This work proposes using the cross validation post hoc estimates of the random
effects (etas) as metrics for identifying covariate models in the population PK/PD
setting, and the Bayesian prediction errors in the y’s for identifying structural models.
First, some background information on population PK/PD will be provided.
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Population pharmacokinetic and pharmacodynamic (PK/PD) modeling is the char-
acterization of the distribution of probable PK/PD outcomes (parameters, concentra-
tions, responses, etc.) in a population of interest. These models consist of fixed and
random effects. The fixed effects describe the relationship between explanatory vari-
ables such as age, body weight, gender, and pharmacokinetic outcomes. The random
effects quantify unexplained variation in PK/PD outcomes.
Population PK models are hierarchical. There is a model for the individual, a
model for the population, and a model for the residual error. The individual model
consists of the curve of drug concentrations over time, a compartmental model. The
pharmacokinetic compartmental model is similar to a black box engineering model.
Each of the compartments is like a black box, where a system of differential equations
is derived based on the law of conservation of mass (Sandler, 1999).
The equations for the PK parameters represent the model for the population in
the hierarchy of models. The PK parameters are modeled with regression equations
containing fixed effects, covariates, and random effects (etas). The vector of random
effects (eta) is assumed to follow a multivariate normal distribution with mean 0 and
variance-covariance matrix Ω. Ω may be diagonal, full block, or block diagonal.
The model for the residual error accounts for overall uncertainty in the concentra-
tions over time. The errors may weighted so that measurements with higher variability
are given less weight compared with measurements with smaller variability.
Hence, population pharmacokinetic models are non-linear mixed effects models.
The differential equations may or may not have a closed-form solution, and are solved
either analytically or numerically. The parameters are estimated using one of the
various algorithms available such as first order conditional estimation with interaction
(FOCEI). See (Wang, 2007) for a mathematical description of these algorithms.
Once model parameters are estimated using an algorithm such as FOCEI, one may
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fix the values of the model estimates and perform a post-hoc calculation to obtain
random effect values (etas) for each subject. Thus, one may fit a model to a subset of
the data and obtain random effect values for the full data set.
2.2.1 Cross-Validation
Cross-validation is a method for evaluating the expected accuracy of a predictive
model. Suppose we have a response variable Y and a predictor variable X and we
seek to estimate Y based on X. Using the observed X’s and Y ’s we may estimate
a function fˆ such that our estimated value of Y (which we call Yˆ ) is equal to fˆ(X).
Cross-validation is an estimate of the expected loss function for estimating Y based
on fˆ(X). If we use squared error loss (as is conventional in population PK modeling),
then cross-validation is an estimate of E
[(
Y − fˆ(X)
)2]
.
A brief explanation of cross-validation is as follows: First, the data is divided into
K partitions of roughly equal size. For the kth partition, a model is fit to predict Y
based on X using the K − 1 other partitions of the data. (Note that the kth partition
is not used to fit the model.) Then the model is used to predict Y based on X for
the data in the kth partition. This process is repeated for k = 1, 2 . . . , K, and the K
estimates of prediction error are combined. Formally, let fˆ−k be the estimated value of
f when the kth partition is removed, and suppose the indices of the observations in the
kth partition are contained in Kk. Then the cross-validation estimate of the expected
prediction error is equal to
1
n
k∑
i=1
∑
j∈Ki
(
yj − fˆ−i(xj)
)2
Here n denotes the number of observations in the data set. For a more detailed discus-
sion of cross-validation, see (Hastie, Tibshirani and Friedman, 2008).
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Cross validation is not often done with population PK modeling (Brendel et al.,
2007). In one case (Bailey, Mora and Shafer, 1996), data was pooled across subjects
to fit a model as though the data were obtained from a single subject. Subjects were
removed, one at a time, and the accuracy of the predicted observations with subsets
of the data was assessed. The method we propose is different because it does not pool
the data across subjects prior to modeling, and we use it to compare candidate mod-
els rather than to assess accuracy of prediction. Another paper (Hooker et al., 2008)
describes removing a subject at a time to estimate model parameters, then predicting
PK parameters using the covariate values for the subject that was removed and com-
paring those with the PK parameters obtained using the full data set, to evaluate the
final model and identify influential individuals. The method we propose is different in
that it uses a post-hoc step to calculate random effect values for the subject that is
removed, and instead of evaluating a final model or identifying influential individuals
we use cross validation to compare candidate models.
2.3 Methods
2.3.1 Comparing models with major structural differences
In this case, a researcher may want to compare models with different numbers of
compartments, such as a one-compartment model with a two-compartment model. This
method is designed to detect differences in models that affect the overall shape of the
curve.
Consider a dataset with subjects i, i = 1, ..., n. Each subject has observations yij
for j = 1, ..., ti (ti being the number of time points or discrete values of the independent
variable for which there are observations for subject i). The statistic can be calculated
as follows.
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For i = 1 to n:
1. Remove subject i from the dataset
2. Fit a mixed effects model to the subset of the data
3. Accept all parameter estimates from the last run, and freeze the parameters to
those values
4. Fit the same model to the whole dataset, without any major iterations, estimat-
ing only the post hoc values of the random effects (Phoenix NLME: NITER=0.
NONMEM: MAXITER=0, POSTHOC=Y)
5. Calculate predicted values for subject i (the subject that was left out)
6. Take the average of the squared individual residuals for the subject that was left
out (over all time points or over all values of the independent variable ti)
Take the average of the quantity in step 6 over all subjects.
This sequence of steps can also be represented by the equation
mPRESS =
1
n
n∑
i=1
ti∑
j=1
(yij − yˆij,−i)2
ti
(2.1)
where yij is the observed value for the ith subject at the jth time point or indepen-
dent variable value. yˆij,−i is the predicted value for the ith subject at the jth time point
or independent variable value in a model where subject i is left out and post hocs are
obtained. The number of time points or independent variable values for which there
are observations for subject i is represented by ti, n is the number of subjects.
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For purposes of exploration, another statistic that takes into account the weighting
can be calculated
wtmPRESS =
1
n
n∑
i=1
ti∑
j=1
WTIRES2ij,−i
ti
,WTIRESij,−i =
√
wtij,−i(yij − yˆij,−i)
σˆ−i
(2.2)
where WTIRESij,−i is the individual weighted residual for subject i at time or
independent variable value j in a model where subject i is left out and post hocs are
obtained, and wtij,−i is the weight defined by the residual error model (equal to the
squared reciprocal of yˆij,−i for constant CV error models or 1 for additive error models),
and σˆ2−i is the estimated residual variance.
When comparing models, the following steps should be applied. If the model with
less parameters has a value of the statistic less than or equal to that of the model with
more parameters, the model with less parameters should be chosen. For cases where
the statistic for the model with more parameters is smaller than that of the model with
less parameters, and furthermore, if the statistic for the model with less parameters is
within one standard error of the statistic of the model with more parameters, the model
with the smaller number of parameters should be chosen. Otherwise, if the model with
more parameters has a value of the statistic that is more than one standard error below
that of the model with less parameters, the model with more parameters should be
chosen. The standard error employed should be that of the model with the smallest
value of the statistic.
Alternatively, one may follow the same procedure, removing more than one subject
at a time. For example, remove 10 percent of subjects at a time, fit a model, obtain
predictions for the subjects left out including the post hoc values of the parameters.
Square the individual residuals, average those over the independent variable for each
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subject, average over subjects.
This method is similar to, or possibly the same as, cross validation methods already
established, though it’s not clear whether current methods include calculating the post
hoc parameter values to obtain predictions for the subjects that are left out.
2.3.2 Comparing covariate models
In this case, a researcher may want to compare models with and without covariate
effects, such as a model with an age effect on clearance versus a model without an age
effect on clearance. This method is designed to detect differences in models that affect
the equations for the parameters.
Consider a dataset with subjects i, i = 1, ..., n. Each subject has observations yij for
j = 1, ..., ti (ti being the number of time points or discrete values of the independent
variable for which there are observations for subject i). The question of interest is
whether or not a fixed effect dPdV for a covariate V should be included in an equation
for a parameter P, having fixed effect tvP and random effect ηP . The equation for P
could have any of the typical forms used in population PK/PD modeling, for example,
P = tvP · (V/mean(V ))dPdV · exp(ηP ) (2.3)
and one wishes to compare it with a model having no covariate effect
P = tvP · exp(ηP ) (2.4)
If a covariate, V, has an effect on a parameter, P, the unexplained error in P, modeled by
ηP , when V is left out of the model tends to have higher variance. By including covariate
V in the model, we wish to reduce the unexplained error in P, which is represented by
ηP . Therefore, metrics involving ηP are useful for determining whether a covariate V
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is needed. While the distribution of ηP under the null and alternative hypotheses is
unknown, cross validation can be performed. We propose a statistic for determining
whether a covariate, V, is needed for explaining variability in a parameter, P, when P
is modeled with a random effect “eta”, ηP .
The statistic can be calculated as follows.
For i = 1 to n:
1. Remove subject i from the dataset
2. Fit a mixed effects model to the subset of the data
3. Accept all parameter estimates from the last run, and freeze the parameters to
those values
4. Fit the same model to the whole dataset, without any major iterations, estimat-
ing only the post hoc values of the random effects (Phoenix NLME: NITER=0.
NONMEM: MAXITER=0, POSTHOC=Y)
5. Square the post hoc eta estimate for the subject that was left out for the parameter
of interest
Take the average of the quantity in step 5 over all subjects.
This sequence of steps can also be represented by the equation
nPRESS =
1
n
n∑
i=1
(ηˆPi,−i)
2 (2.5)
Where ηˆPi,−i is the post hoc “eta” estimate for the ith subject for parameter P in
a model where the ith subject was removed, and n is the number of subjects.
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When comparing models, the following steps should be applied. If the model with
less parameters has a value of the statistic less than or equal to that of the model with
more parameters, the model with less parameters should be chosen. For cases where
the statistic for the model with more parameters is smaller than that of the model with
less parameters, and furthermore, if the statistic for the model with less parameters is
within one standard error of the statistic of the model with more parameters, the model
with the smaller number of parameters should be chosen. Otherwise, if the model with
more parameters has a value of the statistic that is more than one standard error below
that of the model with less parameters, the model with more parameters should be
chosen. The standard error employed should be that of the model with the smallest
value of the statistic.
Alternatively, one may follow the same procedure, removing more than one subject
at a time. For example, remove 10 percent of subjects at a time, fit a model, calculate
the post hoc values for the subjects left out, square the post hoc etas, average them
over subjects.
2.4 Simulation Example 1
A one-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator. The equations for the model are as follows.
dAa
dt
= −Ka · Aa
dA1
dt
= Ka · Aa− Cl · C
C =
A1
V
30
A 10 percent constant CV percentage was simulated for the residual error.
CObs = C * (1 + CEps) where Var(CEps) = 0.01
A fixed effect was added to the absorption rate parameter, Ka. All other parameters
were simulated with fixed and random effects.
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · exp(nCl)
The fixed effects for the PK parameters were assumed to be normally distributed
at the study level (varying across replicates) with means listed below and standard
deviations of 0.1.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvCl) = 7.4
The random effects (nV and nCl) were simulated to be independent and normally
distributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01. A covariate, GENDER, was simulated, so that there were 50 percent males
and 50 percent females. A covariate, BODYWEIGHT, was simulated with a mean of
70 kg for males, 65 kg for females and a standard deviation of 15 for both groups. A
covariate, Age, was simulated, with a mean of 40 years and a standard deviation of 10.
None of the covariates were simulated to have any effect on the parameters. The true
underlying model had no covariate effects. A dose of 5617 was administered at time 0,
as an extravascular dose. Two hundred replicates were simulated. See Figure 2.1 for a
plot of the simulated data.
The base model was a one compartment extravascular model with random effects
for V and Cl and no age effect on clearance. The full model was a one compartment
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Figure 2.1: Simulation Example 1 data
extravascular model with random effects for V and Cl and an age effect on clearance.
Base (correct) model
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · exp(nCl)
Full (incorrect) model
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · (Age/40)dCldAge · exp(nCl)
Where tvKa, tvV, tvCl, and dCldAge are fixed effects parameters to be estimated.
Initial estimates for the fixed effects PK parameters (tvKa, tvV, and tvCl) were set
to the true (simulated) parameter values. The initial estimate for the covariate effect
(dCldAge) was set to -3. The initial estimates of the variances of the random effects
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were all 0.1, close to the true value of 0.01.
2.5 Simulation Example 2
A one-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator. The equations for the model are as follows.
dAa
dt
= −Ka · Aa
dA1
dt
= Ka · Aa− Cl · C
C =
A1
V
A 10 percent constant CV percentage was simulated for the residual error.
CObs = C * (1 + CEps) where Var(CEps) = 0.01
A fixed effect was added to the absorption rate parameter, Ka. All other parameters
were simulated with fixed and random effects. The systemic clearance was simulated
with an age effect.
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · (Age/40)dCldAge · exp(nCl)
The fixed effects (tvKa, tvV, tvCl, and dCldAge) were assumed to be normally
distributed at the study level (varying across replicates) with means listed below and
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standard deviations of 0.05, 0.1, 0.05, and 0.04, respectively.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvCl) = 1.2
mean(dCldAge) = −0.9
The random effects (nV and nCl) were simulated to be independent and normally
distributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01. A covariate, GENDER, was simulated, so that there were 50 percent males
and 50 percent females. A covariate, BODYWEIGHT, was simulated with a mean of
70 kg for males, 65 kg for females and a standard deviation of 15 for both groups. A
covariate, Age, was simulated, with a mean of 40 years and a standard deviation of 10.
The true underlying model had a covariate effect– an age effect on clearance. A dose of
5617 was administered at time 0, as an extravascular dose. Two hundred replicates were
simulated. See Figure 2.2 for a plot of the simulated data, with clearance decreasing
with age.
Figure 2.2: Simulation Example 2 data, by age quartiles
The base model was a one compartment extravascular model with random effects
on V and Cl and no age effect on clearance. The full model was similar to the base
model, but with an age effect included for Cl.
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Base (incorrect) model
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · exp(nCl)
Full (correct) model
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · (Age/40)dCldAge · exp(nCl)
Where tvKa, tvV, tvCl, and dCldAge are fixed effects parameters to be estimated.
Initial estimates for the fixed effects parameters (tvKa, tvV, tvCl, and dCldAge) were
set to the true (simulated) parameter values. The initial estimates of the variances of
the random effects were all 0.1, close to the true values of 0.01.
2.6 Simulation Example 3
A two-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator. The equations for the model are as follows.
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dAa
dt
= −Ka · Aa
dA1
dt
= Ka · Aa− Cl · C − Cl2 · (C − C2)
dA2
dt
= Cl2 · (C − C2)
C =
A1
V
C2 =
A2
V 2
A 10 percent constant CV percentage was simulated for the residual error.
CObs = C * (1 + CEps) where Var(CEps) = 0.01
A fixed effect was added to the absorption rate parameter, Ka. All other parameters
were simulated with fixed and random effects. The systemic clearance was simulated
with an age effect.
Ka = tvKa
V = tvV · exp(nV )
V 2 = tvV 2 · exp(nV 2)
Cl = tvCl · (Age/40)dCldAge · exp(nCl)
Cl2 = tvCl2 · exp(nCl2)
The fixed effects (tvKa, tvV, tvV2, tvCl, tvCl2, and dCldAge) were assumed to be
normally distributed at the study level (varying across replicates) with means listed
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below and standard deviations of 0.05, 0.1, 0.1, 0.05, 0.05, and 0.04, respectively.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvV 2) = 36
mean(tvCl) = 1.2
mean(tvCl2) = 0.62
mean(dCldAge) = −0.9
The random effects (nV, nV2, nCl, and nCl2) were simulated to be independent
and normally distributed at the subject level (varying across subjects) with means of
0 and variances of 0.01. A covariate, GENDER, was simulated, so that there were 50
percent males and 50 percent females. A covariate, BODYWEIGHT, was simulated
with a mean of 70 kg for males, 65 kg for females and a standard deviation of 15 for
both groups. A covariate, Age, was simulated, with a mean of 40 years and a standard
deviation of 10. The true underlying model had a covariate effect– an age effect on
clearance. A dose of 5617 was administered at time 0, as an extravascular dose. Two
hundred replicates were simulated. See Figure 2.3 for a plot of the simulated data, with
clearance decreasing with age.
Figure 2.3: Simulation Example 3 data, by age quartiles
The base model was a two compartment extravascular model with random effects
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on V, V2, Cl, and Cl2 and no age effect on clearance. The full model was similar to
the base model, but with an age effect included for Cl.
Base (incorrect) model
Ka = tvKa
V = tvV · exp(nV )
V 2 = tvV 2 · exp(nV 2)
Cl = tvCl · exp(nCl)
Cl2 = tvCl2 · exp(nCl2)
Full (correct) model
Ka = tvKa
V = tvV · exp(nV )
V 2 = tvV 2 · exp(nV 2)
Cl = tvCl · (Age/40)dCldAge · exp(nCl)
Cl2 = tvCl2 · exp(nCl2)
Where tvKa, tvV, tvV2, tvCl, tvCl2, and dCldAge are fixed effects parameters to
be estimated. Initial estimates for the fixed effects parameters (tvKa, tvV, tvV2, tvCl,
tvCl2, and dCldAge) were set to the true (simulated) parameter values. The initial
estimates of the variances of the random effects were all 0.1, close to the true values of
0.01.
2.7 Simulation Example 4
A one-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator. The equations for the model are as follows.
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dAa
dt
= −Ka · Aa
dA1
dt
= Ka · Aa− Cl · C
C =
A1
V
A 10 percent constant CV percentage was simulated for the residual error.
CObs = C * (1 + CEps) where Var(CEps) = 0.01
A fixed effect was added to the absorption rate parameter, Ka. All other parameters
were simulated with fixed and random effects. The systemic volume was simulated with
a body weight effect. The systemic clearance was simulated with body weight (BW),
age (Age), gender (Gender), and hepatic impairment (HI) effects.
Ka = tvKa
V = tvV · (BW/70)dV dBW · exp(nV )
Cl = tvCl · (BW/70)dCldBW · (Age/40)dCldAge · (1 + dCldG ·Gender)
·(1 + dCldHI ·HI) · exp(nCl)
The fixed effects (tvKa, tvV, tvCl, dVdBW, dCldBW, dCldAge, dCldG, and dCldHI)
were assumed to be normally distributed at the study level (varying across replicates)
with means listed below and standard deviations of 0.05, 0.1, 0.05, 0.1, 0.1, 0.04, 0.05,
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and 0.05 respectively.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvCl) = 1.2
mean(dV dBW ) = 1
mean(dCldBW ) = 0.75
mean(dCldAge) = −0.9
mean(dCldG) = 0.1
mean(dCldHI) = −0.2
The random effects (nV and nCl) were simulated to be independent and normally
distributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01. A covariate, Gender, was simulated, so that there were 50 percent males
(Gender=1) and 50 percent females (Gender=0). A covariate for body weight, BW,
was simulated with a mean of 70 kg for males, 65 kg for females and a standard deviation
of 15 for both groups. A covariate, Age, was simulated, with a mean of 40 years and
a standard deviation of 10. A covariate for hepatic impairment, “HI”, was simulated,
with 70 percent not hepatically impaired (HI=0) and 30 percent hepatically impaired
(HI=1). The true underlying model had five covariate effects– a body weight effect on
volume, and age, body weight, gender, and hepatic impairment effects on clearance.
A dose of 5617 was administered at time 0, as an extravascular dose. Two hundred
replicates were simulated. See Figure 2.4 for a plot of the simulated data.
The base model was a one compartment extravascular model with random effects
on V and Cl, a body weight effect on V, and age, gender, and body weight effects on
clearance. The full model was similar to the base model, but with a hepatic impairment
effect also included for Cl.
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Figure 2.4: Simulation Example 4 data, by hepatic impairment
Base (incorrect) model
Ka = tvKa
V = tvV · (BW/70)dV dBW · exp(nV )
Cl = tvCl · (BW/70)dCldBW · (Age/40)dCldAge · (1 + dCldG ·Gender) · exp(nCl)
Full (correct) model
Ka = tvKa
V = tvV · (BW/70)dV dBW · exp(nV )
Cl = tvCl · (BW/70)dCldBW · (Age/40)dCldAge · (1 + dCldG ·Gender)
·(1 + dCldHI ·HI) · exp(nCl)
Where tvKa, tvV, tvCl, dVdBW, dCldBW, dCldAge, dCldG, and dCldHI are fixed
effects parameters to be estimated. Initial estimates for the fixed effects parameters
were set to the true (simulated) parameter values. The initial estimates of the variances
of the random effects were all 0.1, close to the true values of 0.01.
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2.8 Simulation Example 5
A two-compartment, extravascular model was simulated with six subjects using
Pharsight’s Trial Simulator. The equations for the model are as follows.
dAa
dt
= −Ka · Aa
dA1
dt
= Ka · Aa− Cl · C − Cl2 · (C − C2)
dA2
dt
= Cl2 · (C − C2)
C =
A1
V
C2 =
A2
V 2
A 10 percent constant CV percentage was simulated for the residual error.
CObs = C * (1 + CEps) where Var(CEps) = 0.01
A fixed effect was added to the absorption rate parameter, Ka. All other parameters
were simulated with fixed and random effects.
Ka = tvKa
V = tvV · exp(nV )
V 2 = tvV 2 · exp(nV 2)
Cl = tvCl · exp(nCl)
Cl2 = tvCl2 · exp(nCl2)
The fixed effects for the PK parameters were assumed to be normally distributed
at the study level (varying across replicates) with means listed below and standard
deviations of 0.1, except in this example the fixed effect for Ka was simulated with a
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standard deviation of 0.05 because when the absorption rate was smaller the portion of
the curve for the first compartment became less pronounced in relation to the portion
for the second compartment. Having a smaller standard deviation for Ka increased
the chance that all the simulated profiles would have a characteristic two compartment
shape.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvV 2) = 34
mean(tvCl) = 7.4
mean(tvCl2) = 1.2
The random effects (nV, nV2, nCl, and nCl2) were simulated to be normally distributed
at the subject level (varying across subjects) with means of 0 and variances of 0.01.
A covariate, GENDER, was simulated, so that there were 50 percent males and 50
percent females. A covariate, BODYWEIGHT, was simulated with a mean of 70 kg for
males, 65 kg for females and a standard deviation of 15 for both groups. A covariate,
Age, was simulated, with a mean of 40 years and a standard deviation of 10. The true
underlying model had no covariate effects. A dose of 5617 was administered at time 0,
as an extravascular dose. One hundred replicates were simulated. See Figure 2.5 for a
plot of the simulated data.
Pharsights Phoenix NLME was used to fit models to the simulated data. A base
model with one compartment was fit to the simulated data. A full model with two
compartments was fit.
Base (incorrect) model
Ka = tvKa
V = tvV · exp(nV )
Cl = tvCl · exp(nCl)
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Figure 2.5: Simulation Example 5 data
Full (correct) model
Ka = tvKa
V = tvV · exp(nV )
V 2 = tvV 2 · exp(nV 2)
Cl = tvCl · exp(nCl)
Cl2 = tvCl2 · exp(nCl2)
Where tvKa, tvV, tvV2, tvCl, and tvCl2 are fixed effects parameters to be esti-
mated. Initial estimates for the fixed effects parameters (tvKa, tvV, tvV2, tvCl, and
tvCl2) were set to the true (simulated) parameter values. The initial estimates of the
variances of the random effects were all 0.1, close to the true values of 0.01.
2.9 Computational details
Pharsights Phoenix NLME was used to fit models to the simulated data from the
command line. First, R was used to split replicates of the simulated datasets into
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different files, then to split replicate datasets into training datasets in separate folders.
Each training dataset consisted of the full dataset for the given replicate except with
concentrations and amounts set to missing for one subject. In each folder with each
training dataset resided the full dataset for the corresponding replicate. One batch
file was used to call another batch file to execute NLME in all the folders until all
training datasets and all replicates were processed. First the batch files were called to
run NLME with the training datasets to obtain model parameter estimates using the
Lindstrom-Bates method (Lindstrom and Bates, 1990), then called to run NLME again
in the same folder with the full datasets without any major iterations, starting from
the last solution (!iflagrestart=1 in nlmeflags.asc), to obtain post hoc estimates for the
subjects that had been removed.
This entire process was completed for a base model and a full model for each sim-
ulation scenario.
2.10 Simulation Results
The results of the simulations are summarized in Tables 2.1, 2.2, 2.3, 2.4, and 2.5.
If the true underlying model was the base model (as in the first scenario), a model
comparison method was considered correct if it selected the base model. For AIC, BIC,
and nPRESS, if the value for the base model was smaller than that of the full model,
it was considered to be correct. For the mPRESS and wtmPRESS, the method was
considered to be correct if the value of the statistic for the base model was less than
the value of statistic for the full model. Otherwise, if the value of the statistic for the
full model was smaller, it was still correct if the statistic for the base model was within
one standard error of the statistic for the full model (employing the standard error of
the statistic for the full model).
If the true underlying model was the full model, a model comparison method was
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Table 2.1: Proportion correct out of 200 replicates
True Model Comparison AIC BIC wtmPRESS mPRESS nPRESS
1 Cpt 1 Cpt, Age-Cl 0.885 0.945 0.940 0.965 0.970
1 Cpt, Age-Cl 1 Cpt 0.985 0.930 0.000 0.000 0.925
2 Cpt, Age-Cl 2 Cpt 0.975 0.940 0.005 0.010 0.930
1 Cpt, BW-V; 1 Cpt, BW-V; 0.715 0.640 0.015 0.005 0.970
BW-Cl, G-Cl, BW-Cl, G-Cl,
Age-Cl, HI-Cl Age-Cl
2 Cpt 1 Cpt 1.00* 1.00* 1.00* 1.00* N/A
Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
*Based on 100 replicates
considered correct if it selected the full model. For AIC, BIC, and nPRESS, if the
value was greater for the base model than for the full model, it was considered correct.
For the mPRESS and wtmPRESS, the method was considered incorrect if the value of
the statistic for the base model was smaller than the value of the statistic for the full
model. Otherwise, if the value of the statistic for the base model was greater than the
value of the statistic for the full model plus one standard error, it was considered to be
correct (employing the standard error of the statistic for the full model).
The modified nPRESS statistic was correct in 97.0 percent of the 200 cases where
the true one compartment underlying model had no covariate effect, whereas AIC was
correct in 88.5 percent of cases and BIC was correct in 94.5 percent of cases. It correctly
identified the full model when the true underlying model was a one compartment model
with an age effect on clearance in 92.5 percent of the 200 cases, where AIC found the
correct model in 98.5 percent of cases and BIC found the correct model in 93 percent
of cases. When the true underlying model was two compartment with an age effect
on clearance, nPRESS was correct in 93.0 percent of cases, whereas AIC and BIC
were correct in 97.5 and 94.0 percent of cases, respectively. When the true underlying
46
model was one compartment with a body weight effect on volume, and body weight,
gender, age, and hepatic impairment effects on clearance, nPRESS was correct in 97.0
percent of cases, whereas AIC and BIC were correct in 71.5 and 64.0 percent of cases,
respectively.
To emphasize the fact that the mPRESS and wtmPRESS statistics, which use the
predicted values rather than the random effects for the parameters, should not be used
for comparing different covariate models in the population PK/PD setting, mPRESS
and wtmPRESS were calculated for all scenarios. They were wrong almost every time
when the true model had a covariate effect. The predicted values are just as accurate
with and without the covariate effect when the true model has a covariate effect, because
the etas (e.g., nCl) will always compensate for a missing covariate in a parameter (e.g.,
Cl). This is why the nPRESS and not the mPRESS, nor the wtmPRESS, should be
employed for situations when one wishes to compare different covariate models.
All four applicable methods (AIC, BIC, mPRESS, and wtmPRESS) correctly iden-
tified the two compartment model with random effects on V, V2, Cl, and Cl2 as the
correct model when the base model was a one compartment model with random effects
on V and Cl in 100 out of 100 cases. This finding is of interest because the standard
likelihood ratio test cannot be applied when there are random effects in the full model
that aren’t present in the base model.
While AIC and BIC were not correct in all cases, the average AIC and BIC were
smaller for the true underlying models when averaging across replicates.
For each replicate, the value of mPRESS, wtmPRESS, or nPRESS has a standard
error associated with it. The standard error for each replicate is calculated as the
sample standard error of mPRESS, wtmPRESS, or nPRESS divided by the square
root of the number of subjects. The standard errors are summarized in Tables 2.3 and
2.4, along with the mean values of nPRESS, mPRESS, and wtmPRESS. The values
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Table 2.2: Summary of AIC and BIC in simulation scenarios
AIC BIC
True Model Comparison Base Full Base Full
1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 384 404 401 424
SD 114 115 114 115
1 Cpt, 1 Cpt N 200 200 200 200
Age-Cl Mean 1106 1093 1124 1113
SD 25 25 25 25
2 Cpt, 2 Cpt N 200 200 200 200
Age-Cl Mean 1039 1026 1068 1058
SD 27 27 29 29
1 Cpt, BW-V; 1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 1106 1100 1135 1132
Age-Cl, HI-Cl Age-Cl SD 33 32 33 32
2 Cpt 1 Cpt N 100 100 100 100
Mean 648 417 664 443
SD 218 26 218 26
Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
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Table 2.3: Summary of nPRESS in simulations
nPRESS SE
True Model Comparison Base Full Base Full
1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 0.136 0.919 0.022 0.403
SD 0.236 0.920 0.032 0.512
1 Cpt, 1 Cpt N 200 200 200 200
Age-Cl Mean 0.078 0.012 0.031 0.005
SD 0.056 0.010 0.022 0.005
2 Cpt, 2 Cpt N 200 200 200 200
Age-Cl Mean 0.144 0.024 0.077 0.020
SD 0.728 0.155 0.453 0.155
1 Cpt, BW-V; 1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 1.700 0.124 0.626 0.081
Age-Cl, HI-Cl Age-Cl SD 2.577 0.281 2.515 0.214
Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
of nPRESS tended to be lower for the true underlying model in all scenarios. Because
the eta will always compensate for a missing covariate, the mPRESS and wtmPRESS
statistics should not be used for comparing covariate models, although they did perform
well when the true underlying model had no covariate effect as well as for identifying
the correct structural model.
2.11 Indomethacin Example
Pharsights Phoenix NLME was used to fit models to the published indomethacin
dataset (Kwan et al., 1976). The indomethacin dataset, containing six subjects with
eleven observations each, was fit using a two-compartment IV bolus model with Clear-
ance parameterization and a proportional residual error model. Concentration units of
ug/mL were assumed, and a dose of 25000 ug at 0 hours was assumed. Random effects
were added to the PK parameters V, Cl, V2, and Cl2, in the form ThetaX*exp(nX),
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Table 2.4: Summary of mPRESS in simulations
mPRESS SE
True Model Comparison Base Full Base Full
1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 41.1 46.4 13.3 18.5
SD 58.4 82.0 51.6 73.6
1 Cpt, 1 Cpt N 200 200 200 200
Age-Cl Mean 247 254 45.6 47.2
SD 54.0 59.0 24.4 25.5
2 Cpt, 2 Cpt N 200 200 200 200
Age-Cl Mean 159 199 28.0 59.9
SD 34.9 171 12.5 160
1 Cpt, BW-V; 1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 323 472 85.1 173
Age-Cl, HI-Cl Age-Cl SD 116 401 72.2 284
2 Cpt 1 Cpt N 100 100 100 100
Mean 206.11 30.28 32.32 8.32
SD 90.3 9.60 20.7 5.74
Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
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Table 2.5: Summary of wtmPRESS in simulations
wtmPRESS SE
True Model Comparison Base Full Base Full
1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 1.14 1.20 0.157 0.176
SD 0.303 0.388 0.064 0.154
1 Cpt, 1 Cpt N 200 200 200 200
Age-Cl Mean 0.967 1.01 0.144 0.154
SD 0.133 0.130 0.120 0.111
2 Cpt, 2 Cpt N 200 200 200 200
Age-Cl Mean 1.0096 1550* 0.154 1550*
SD 0.0995 21700* 0.071 21700*
1 Cpt, BW-V; 1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 1.25 2.78 0.305 1.56
Age-Cl, HI-Cl Age-Cl SD 0.485 11.6 0.432 11.3
2 Cpt 1 Cpt N 100 100 100 100
Mean 14.7 1.14 3.09 0.233
SD 10.1 0.143 2.86 0.130
Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
*One of the replicates (161) had an inflated value for wtmPRESS. One subject was
significantly younger than the others, and the effect of age on clearance was estimated
to be around -22 instead of the true value of -0.9 in the model where this subject was
left out. Hence the younger subject had inflated residuals.
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Table 2.6: Theta from final model of Indomethacin dataset
Parameter Estimate Units Stderr Stderr%
tvV 8898 mL 574.84 6.46
tvV2 19527.3 mL 3169.70 16.23
tvCl 7905.99 mL/h 608.53 7.70
tvCl2 5252.15 mL/h 768.93 14.64
stdev0 0.1440 0.02 13.25
stdev0 = estimated residual standard deviation
prefix of ’tv’ denotes fixed effect or typical value
where X is the parameter of interest.
Exploratory analysis (plot, Figure 4.2) showed two compartment PK. Individual
initial estimates were obtained using the curve stripping method (Gibaldi and Perrier,
1975) with a WinNonlin Classic model. The averages of the individual PK parameters
were used as initial estimates for the pop PK model.
Figure 2.6: Concentration versus time from Indomethacin dataset
The model appeared to fit well based on diagnostic plots (Figures 4.3, 4.4, 4.5).
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Table 2.7: Omega from final model of Indomethacin dataset
nV nCl nV2 nCl2
nV 0.0017
nCl 0 0.0338
nV2 0 0 0.0666
nCl2 0 0 0 0.1202
Shrinkage 0.7064 0.0329 0.3321 0.0727
The shrinkage was high for nV, but it was kept in. The relative standard errors for
the fixed effect parameter estimates were all well below 30. The value of the original
(Allen, 1974) PRESS statistic for the final model was 1.54, based on removal of 66 data
points, one at a time. The average of Allen’s PRESS over all data points was 0.02337.
The likelihood ratio test and the mPRESS statistic were used to compare a two
compartment model with a one compartment model, without any random effects on the
PK parameters (nV, nCl, nV2, nCl2 were removed so that comparison could be made
with likelihood ratio test). The likelihood ratio test favored the two compartment model
(p <0.0001). The mPRESS (without post hocs) was in agreement with the likelihood
ratio test, having a value of 0.1419 (SE 0.03393) for the one compartment model,
and 0.0428 (SE 0.01355) for the two compartment model. Because 0.0428 + 0.01355
<0.1419, the mPRESS (without post hocs) favored the two compartment model.
The mPRESS with post hocs also favored the full (two compartment) model over
the base (one compartment) model, when the random effects were added back in. The
mPRESS (with post hocs) for the full model was 0.01679 (SE 0.004194) and 0.1406
(SE 0.03358) for the base model.
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Figure 2.7: Final model of Indomethacin dataset
2.12 Theophylline Example
Pharsights Phoenix NLME was used to fit models to the published theophylline
dataset (Boeckmann, Sheiner and Beal, 1992). The theophylline dataset, contain-
ing twelve subjects with eleven observations each, was fit using a one-compartment
extravascular model with Clearance parameterization and an additive residual error
model. Concentration units of mg/L were assigned, and doses of 267-320 mg/kg were
given at 0 hours. A covariate for weight in kg was present in the dataset. Random ef-
fects were added to the PK parameters Ka, V, and Cl and in the form ThetaX*exp(nX),
where X is the parameter of interest.
Exploratory analysis (plot, Figure 2.10) showed one compartment PK. Initial esti-
mates for Ka, V, and Cl were 2, 1, and 1, respectively.
The likelihood ratio test and the mPRESS statistic were used to compare a model
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Figure 2.8: Residuals from final model of Indomethacin dataset
with a time lag parameter (tlag) to a model without a tlag parameter, without a
random effect on the tlag parameter. The likelihood ratio test favored the tlag model
(p <0.0001). The mPRESS was in agreement with the likelihood ratio test, having a
value of 0.2546 (SE 0.05727) for the model with tlag, and 0.3927 (SE 0.10001) for the
model without tlag. Because 0.2567 + 0.05727 <0.3927, the mPRESS favored the tlag
model.
The likelihood ratio test and the nPRESS statistic were used to compare a model
with the tlag parameter and body weight effect on Ka to the model with the tlag
parameter. The covariate plots for the model with tlag seemed to indicate a weight
effect on Ka might be needed (Figure 2.11).
Ka = tvKa · (wt/mean(wt))dKadwt · exp(nKa)
The likelihood ratio test had a borderline result (p = 0.0667). The nPRESS favored
the full model with a tlag and a weight effect on Ka, having a value of 0.06220 (SE
0.02942) for the full (tlag and wt) model, and 0.7819 (SE 0.2846) for the base (tlag)
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Figure 2.9: Observed versus predicted values for Indomethacin model
model. Because 0.06220 + 0.02942 <0.7819, the nPRESS favored the full model with
tlag and wt.
2.13 Discussion
Cross validation can be used to identify structural models and covariate models
for mixed effects longitudinal modeling, such as population PK/PD modeling. The
nPRESS method outperformed AIC and BIC for finding the true underlying model
when the true underling model had five covariates in a simulation study. It was specific
enough not to find a covariate effect when one did not exist in the true underlying model.
The mPRESS was in agreement with the likelihood ratio test in a real data example
comparing models with different numbers of compartments. It correctly identified the
two compartment model in a simulation study with a one compartment model for
comparison.
In the Theophylline example, the population covariate plots (etas versus covariates)
seemed to suggest a weight effect on Ka, while the likelihood ratio test gave a result of
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Figure 2.10: Concentration versus time from Theophylline dataset
borderline significance. The nPRESS statistic clearly favored the model with the weight
effect on Ka. It seems that the likelihood ratio test cannot always identify covariate
effects when they exist, therefore it is useful to have another method that can elucidate
the underlying model.
These modified average PRESS statistics are easier to calculate (less computation-
ally intensive) than the original PRESS statistic (Allen, 1974) when there are multiple
observations per subject. The methods proposed in this paper are no more computa-
tionally intensive than bootstrapping, which is commonly done in population PK/PD
modeling. Ten fold cross validation (removal of 10 percent of cases at a time) can be
performed if it becomes cumbersome taking one subject out at a time, as long as the
subset of ninety percent of the data can support the model of interest and is fairly well
balanced in the observed covariate values.
This method might be applied with modifications in the linear mixed effects and
generalized linear mixed effects modeling setting.
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Figure 2.11: Eta versus covariate plots for Theophylline dataset
Note that as a fairly small number of replicates were generated for the simulation
studies, this was not an attempt to estimate the true proportion of times the statistics
will select the correct model in the scenarios that were considered. It was simply to
show that the methods proposed in this paper are worth considering. More extensive
simulation studies would need to be completed in order to estimate the true proportions.
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Chapter 3
Automated Model Building
Procedure
3.1 Overview
One problem when doing population modeling, is that there may be several co-
variates to consider and it is not feasible to fit all possible covariate models. It has
been found that the average squared cross validation post hoc eta is a useful metric for
identifying the correct covariate model. This article proposes a combination of stepwise
and cross validation procedures with shrinkage and the average squared cross validation
post hoc eta as a criteria for selecting covariates for inclusion in population PK/PD
models.
3.2 Introduction
A commonly used method for automated covariate selection in population PK/PD
modeling is forward addition then backward elimination. It is often referred to as
“stepwise”, though it’s different from the stepwise procedure used in traditional linear
regression in that it does forward once, then backward once (Jonsson and Karlsson,
1998). Another method is GAM (Mandema, Verotta and Sheiner, 1992). A comparison
of these methods can be found in (Wahlby, Jonsson and Karlsson, 2002). Maitre first
proposed looking at the plots of the random effects versus the covariates to aid covariate
model selection (Maitre et al., 1991). It was found that tree based modeling with cross
validation to determine the tree size can help identify possible covariate models (Jonsson
and Karlsson, 1999), but it does not seem that the cross validation method described
involved re-fitting of the population model. This paper further explores the use of cross
validation for automated covariate selection, with cross validation in the post hoc etas
obtained from re-fitting population models.
When covariate effects are present in an underlying population PK/PD model, a
misspecification of failing to include a covariate effect may not hurt the overall predictive
performance of the model in the outcome variable or concentration. Random effects in
the pharmacokinetic parameters can make up for the lack of the covariate. Therefore,
cross validation metrics that involve the predicted outcome or concentration errors will
often fail to identify a covariate effect (as shown in paper 2). AIC and BIC are also
error prone when there are several covariates (as shown in paper 2). Likelihood based
approaches can result in inflated Type I error rates (Bertrand et al., 2009).
This work proposes a variation of the traditional stepwise model building procedure,
with shrinkage (Karlsson and Savic, 2007) (Savic and Karlsson, 2007) as a primary
consideration, and the average of the squared post hoc estimates of the random effects
obtained from cross validation as a secondary consideration for identifying complex
covariate models in the population PK/PD setting. First, some background information
on population PK/PD will be provided.
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3.3 Methods
3.3.1 Comparing covariate models
This method was already introduced and evaluated in a separate paper by the same
authors. It is reiterated here to show the calculation formula and decision process. In
this case, a researcher may want to compare models with and without covariate effects,
such as a model with an age effect on clearance versus a model without an age effect
on clearance. This method is designed to detect differences in models that affect the
equations for the parameters.
Consider a dataset with subjects i, i = 1, ..., n. Each subject has observations yij for
j = 1, ..., ti (ti being the number of time points or discrete values of the independent
variable for which there are observations for subject i). The question of interest is
whether or not a fixed effect dPdV for a covariate V should be included in an equation
for a parameter P, having fixed effect tvP and random effect ηP . The equation for P
could have any of the typical forms used in population PK/PD modeling, for example,
P = tvP · (V/mean(V ))dPdV · exp(ηP ) (3.1)
and one wishes to compare it with a model having no covariate effect
P = tvP · exp(ηP ) (3.2)
If a covariate, V, has an effect on a parameter, P, the unexplained error in P, modeled by
ηP , when V is left out of the model tends to have higher variance. By including covariate
V in the model, we wish to reduce the unexplained error in P, which is represented by
ηP . Therefore, metrics involving ηP are useful for determining whether a covariate V
is needed. While the distribution of ηP under the null and alternative hypotheses is
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unknown, cross validation can be performed. We propose a statistic for determining
whether a covariate, V, is needed for explaining variability in a parameter, P, when P
is modeled with a random effect “eta”, ηP .
The statistic can be calculated as follows.
For i = 1 to n:
1. Remove subject i from the dataset
2. Fit a mixed effects model to the subset of the data
3. Accept all parameter estimates from the last run, and freeze the parameters to
those values
4. Fit the same model to the whole dataset, without any major iterations, estimat-
ing only the post hoc values of the random effects (Phoenix NLME: NITER=0.
NONMEM: MAXITER=0, POSTHOC=Y)
5. Square the post hoc eta estimate for the subject that was left out for the parameter
of interest
Take the average of the quantity in step 5 over all subjects.
This sequence of steps can also be represented by the equation
nPRESS =
1
n
n∑
i=1
(ηˆPi,−i)
2 (3.3)
Where ηˆPi,−i is the post hoc “eta” estimate for the ith subject for parameter P in
a model where the ith subject was removed, and n is the number of subjects.
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When comparing models, the following steps should be applied. If the model with
less parameters has a value of the statistic less than or equal to that of the model with
more parameters, the model with less parameters should be chosen. For cases where
the statistic for the model with more parameters is smaller than that of the model with
less parameters, and furthermore, if the statistic for the model with less parameters is
within one standard error of the statistic of the model with more parameters, the model
with the smaller number of parameters should be chosen. Otherwise, if the model with
more parameters has a value of the statistic that is more than one standard error below
that of the model with less parameters, the model with more parameters should be
chosen. The standard error employed should be that of the model with the smallest
value of the statistic.
Alternatively, one may follow the same procedure, removing more than one subject
at a time. For example, remove 10 percent of subjects at a time, fit a model, calculate
the post hoc values for the subjects left out, square the post hoc etas, average them
over subjects.
3.3.2 Automated Model Selection Procedure
When there are multiple covariates to consider, use this procedure.
1. Start with the base population model with random effects on all of the parameters
and no covariates (check plots prior to this step to make sure overall model
structure as well as the form of the residual error model are good). Use the
eta versus covariate plots to determine the appropriate form for the different
potential covariate effects.
2. If none of the random effects have shrinkages below 0.3 in the base model, stop.
Otherwise, identify the parameter associated with the random effect with the
lowest shrinkage. Calculate nPRESS for the base model.
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3. For the parameter identified in the previous step, calculate nPRESS and the
standard error of nPRESS for all univariate covariate models. Find the covariate
that gives the biggest reduction in nPRESS over the base model. If it is smaller
than that of the base model, and still smaller when one standard deviation (of the
nPRESS of the full model) is added, include that covariate effect in the model for
the given parameter, fit the model without cross validation (this is now the current
working model), and go on to the next step. Otherwise, if none of the potential
covariates meet the criterion, then determine whether any other random effects
have shrinkages below 0.3 in the base model. If none of the remaining random
effects have shrinkages below 0.3, then stop. Otherwise, identify the parameter
with the next lowest shrinkage and repeat this step.
4. In the current working model, fitted without cross validation, if none of the ran-
dom effects have shrinkages below 0.3, stop. Otherwise, identify the parameter
that corresponds to the random effect with the lowest shrinkage in the current
working model. If all the covariate models have already been considered for this
parameter, identify the parameter that corresponds to the random effect with the
next lowest shrinkage.
5. For the parameter identified in the previous step, calculate nPRESS for each of
the remaining potential covariates modeled with the covariate(s) already added.
Find the one that gives highest reduction in nPRESS over the nPRESS of the
current working model. If value of nPRESS is still smaller when one standard
deviation is added, add that covariate to the model for the parameter of interest
(current working model now has an additional covariate effect). Otherwise, if
none of the remaining potential covariates meet the criterion, then stop (current
working model is unchanged).
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6. Repeat steps 4-5 (the last two steps) until none of the remaining covariates meet
criteria for entry (none of the random effects have shrinkages below 0.3 or it
increases nPRESS or decreases nPRESS but the decrease is within one standard
deviation to add more parameters).
3.4 Remifentanil Example
Pharsights Phoenix NLME was used to fit models to the published remifentanil
dataset (Minto et al., 1997). The remifentanil dataset, containing sixty five subjects,
was fitted using a three-compartment IV infusion model with Clearance parameteriza-
tion and a proportional residual error model. Random effects were added to the PK
parameters V, Cl, V2, Cl2, V3, and Cl3 in the form ThetaX*exp(nX), where X is the
parameter of interest.
Figure 3.1: Concentration versus time from Remifentanil dataset
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Exploratory analysis (plot, Figure 3.1) showed three compartment PK. This partic-
ular example was difficult because only a few subjects contributed data for the third
compartment (in Figure 3.1, only a few subjects show full three compartment PK).
Individual initial estimates were obtained using the curve stripping method (Gibaldi
and Perrier, 1975) with a WinNonlin Classic model. The weighted averages of the in-
dividual PK parameters were used as initial estimates for the pop PK model, with the
reciprocal of the standard deviation of the estimate as the weight. With these values,
the Naive Pooled engine (which pools data as though it came from a single subject, but
still taking into account different dosing, and all random effects except a residual error
term are removed) was used to further refine the initial estimates for the fixed effects
in the base population model.
Next, QRPEM (Leary and Dunlavey, 2012) was used to fit the population base
model. The additive error model for the residual error appeared to show a trend in
CWRES versus PRED (plot, Figure 3.2). When the residual error model was changed
to multiplicative (constant CV) weighting, this trend was diminished (plot, Figure 3.4).
Figure 3.2: Residuals with Additive residual error model
Prior to covariate selection with the automated procedure described in this paper,
the subject numbers were randomized because there were clusters of similar subjects
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Table 3.1: Theta from final model of Remifentanil dataset
Parameter Estimate Units Stderr Stderr%
tvV 5.25 0.297 5.66
tvV2 9.68 0.534 5.51
tvV3 10.82 L 0.802 7.41
tvCl 2.39 0.048 2.00
tvCl2 1.55 0.089 5.72
tvCl3 0.08 L/min 0.002 2.35
dCldAGE -0.29 0.037 -12.79
dCldBSA 0.68 0.130 19.13
dCl2dAGE -0.47 0.118 -24.93
dV2dMALE0 -0.27 0.062 -22.41
dVdBSA 1.93 0.447 23.15
dV2dAGE -0.44 0.088 -20.06
stdev0 0.14 0.001 0.87
stdev0 = estimated residual standard deviation
prefix of ’tv’ denotes fixed effect or typical value
in the dataset. The method was applied with approximately ten-fold cross validation
(five subjects removed at a time). Third compartment covariate effects were not going
to be considered to avoid over-fitting and because only a few subjects contributed data
for the third compartment. The steps taken are summarized in the appendix.
Once covariate model selection was finished, the covariance model selection was
completed by first considering whether any random effects could be removed. The
random effect for the volume of the third compartment had a high shrinkage value
(above 0.3), and so it was removed. Next, scatter plots of etas versus etas were inspected
for trends suggesting correlation between the random effects. A trend was found for nCl,
nV2, and nCl2. The final Omega matrix was block-diagonal to reflect this relationship.
Later, when predictive check was performed, the variance for nCl3 appeared to be
inflated, so that random effect was removed as well.
The model appeared to fit well based on diagnostic plots (Figures 3.3, 3.4, 3.5),
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Table 3.2: Omega from final model of Remifentanil dataset
nV nCl nV2 nCl2
nV 0.100
nCl 0 0.019
nV2 0 0.029 0.095
nCl2 0 0.035 0.093 0.161
Correlation
nV 1
nCl 0 1
nV2 0 0.689 1
nCl2 0 0.634 0.746 1
Shrinkage 0.128 0.028 0.051 0.086
except for in the third compartment (at the tails), where the concentrations began to dip
below the limit of quantification. This might have been helped by keeping the random
effects for Cl3 and V3, but with high shrinkage for nV3 and a poor estimate for the
variance of nCl3 (as determined by a visual predictive check, not shown), the random
effects for V3 and Cl3 were removed to keep the model as parsimonious as possible.
The relative standard error percentages for the fixed effect parameter estimates were
all below 30 percent.
For final model validation, a visual predictive check was performed (Figure 3.6).
Assuming the final model parameters were correct, concentration values were simulated
based on the model assumptions. Simulated quantiles were plotted against observed
data and quantiles of observed data and found to be in fairly good congruence.
3.5 Simulation Example
A three-compartment, IV infusion model was simulated with sixty five subjects
using Pharsight’s Phoenix NLME. The equations for the model are as follows.
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Figure 3.3: Final model of Remifentanil dataset
Figure 3.4: Residuals from final model of Remifentanil dataset
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Figure 3.5: Observed versus predicted values from Remifentanil model
Figure 3.6: Predictive check from final Remifentanil model
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dA1
dt
= In(t)− Cl · C − Cl2 · (C − C2)− Cl3 · (C − C3)
dA2
dt
= Cl2 · (C − C2)
dA3
dt
= Cl3 · (C − C3)
C =
A1
V
C2 =
A2
V 2
C3 =
A3
V 3
where In(t) represents a constant rate infusion of the amounts and rates recorded
in the Remifentanil dataset (Minto et al., 1997). A 14 percent constant CV percentage
was simulated for the residual error.
CObs = C * (1 + CEps) where Var(CEps) = 0.0196
A covariate, “MALE”, was simulated, so that there were approximately 50 percent
males and 50 percent females (as in the original dataset). The covariates, body surface
area, “BSA”, and “AGE”, were set to the values in the original Remifentanil dataset.
All parameters were simulated with fixed effects, and random effects on V, Cl, V2,
and Cl2. Several covariate effects were simulated: Age and BSA effects on Cl and V2,
age effects on Cl2 and V, and a gender effect on V. This covariate model was slightly
different than the one found in the analysis of the real data, to see whether the method
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would select a different model if the true underlying model was different.
V = tvV · (AGE/mean(AGE))dV dAGE · exp(dV dMALE0 · (MALE0)) · exp(nV )
V 2 = tvV 2 · (BSA/mean(BSA))dV 2dBSA · (AGE/mean(AGE))dV 2dAGE · exp(nV 2)
V 3 = tvV 3
Cl = tvCl · (AGE/mean(AGE))dCldAGE · (BSA/mean(BSA))dCldBSA · exp(nCl)
Cl2 = tvCl2 · (AGE/mean(AGE))dCl2dAGE · exp(nCl2)
Cl3 = tvCl3
The fixed effects were set to the following values.
tvV = 5.83
tvV 2 = 8.65
tvV 3 = 11.84
tvCl = 2.38
tvCl2 = 1.54
tvCl3 = 0.08
dCldAGE = −0.30
dCldBSA = 0.61
dV 2dBSA = 0.74
dV 2dAGE = −0.42
dCl2dAGE = −0.39
dV dAGE = −0.39
dV dMALE0 = −0.35
The random effects (nV, nV2, nCl, and nCl2) were simulated to be normally distributed
at the subject level (varying across subjects) with means of 0 and variance-covariance
matrix given below. Ten replicates were simulated. See Figure 3.7 for a plot of the
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Table 3.3: Omega for simulation
nCl nCl2 nV2 nV
nCl 0.02
nCl2 0.04 0.17
nV2 0.03 0.10 0.11
nV 0.00 0.00 0.00 0.07
Figure 3.7: Simulated data
simulated data.
Once the data was simulated, the subject numbers were randomized for cross val-
idation. Pharsights Phoenix NLME was used to fit models to the simulated data in
batch mode using the automated covariate selection procedure described in this paper,
as well as with stepwise with AIC and BIC as criteria. Initial estimates for the fixed
effects parameters (tvV, tvV2, tvV3, tvCl, tvCl2, and tvCl3) were set to the true (sim-
ulated) parameter values. Initial estimates for the covariate effects were set to 0. The
initial estimates of the variances of the random effects were all 0.1. The R program
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Table 3.4: Models chosen for each replicate
Replicate Parameter Shrinkage-nPRESS AIC BIC
1 V Male, Age Age, Male Age, Male
1 V2 Age Age, BSA BSA
1 Cl Age, BSA Age, BSA Age, BSA
1 Cl2 Age, Male
2 V Age, Male Age, Male Age, Male
2 V2 Age Age, Male Age
2 Cl Age, BSA Age, BSA Age, BSA
2 Cl2 Age
3 V Age, Male Age, Male Age, Male
3 V2 Age Age, Male, BSA Age
3 Cl Age Age, Male, BSA Age, BSA
3 Cl2 Age Age, Male Age
4 V Male, Age Age, Male Age, Male
4 V2 Age, BSA Age, BSA Age, BSA
4 Cl Age, BSA Age, BSA Age, BSA
4 Cl2 Age Age Age
5 V Age, Male Age, Male Age, Male
5 V2 Age Age, BSA Age
5 Cl Age, BSA Age, BSA Age, BSA
5 Cl2 Age Age Age
was used to parse the output from the NLME batch models.
3.6 Simulation Results
The results of the simulations are summarized in Tables 3.4 and 3.5.
AIC tended to select models with too many covariates. BIC and Shrinkage-nPRESS
tended to select models with too few covariates. In replicate four, all three methods
selected the true underlying model.
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Table 3.5: Models chosen for each replicate (cont’d)
Replicate Parameter Shrinkage-nPRESS AIC BIC
6 V Age, Male Age, Male Age, Male
6 V2 Age Age, BSA Age
6 Cl Age Age, Male, BSA Age, BSA
6 Cl2 Age Age Age
7 V Male, Age Age, Male Age, Male
7 V2 Age Age Age
7 Cl Male, Age Age, Male, BSA Age, Male
7 Cl2 Age Age Age
8 V Male, Age Age, Male Age, Male
8 V2 Age Age, Male Age
8 Cl Age, BSA Age, BSA Age, BSA
8 Cl2 Age Age Age
9 V Male, Age Age, Male Male
9 V2 Age Age, Male, BSA Age
9 Cl Age Age, BSA Age, BSA
9 Cl2 Age, Male Age
10 V Age, Male Age, Male Age, Male
10 V2 BSA BSA BSA
10 Cl Age, BSA Age, BSA Age, BSA
10 Cl2 Male, BSA
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3.7 Discussion
The Shrinkage-nPRESS automated covariate selection method appeared to select
a reasonable model in the real data analysis. In the simulation, BIC and Shrinkage-
nPRESS performed similarly, while AIC selected models with too many covariates.
One might consider decreasing the shrinkage cutoff from 0.3 to 0.2 to avoid overfit-
ting. In order to capture more of the variables that should be added, one might modify
the method to reconsider adding more covariates to a parameter once covariates are
added to other parameters.
This method might be applied with modifications in the linear mixed effects and
generalized linear mixed effects modeling setting.
Note that as a fairly small number of replicates were generated for the simulation
studies, this was not an attempt to estimate the true proportion of times the statistics
will select the correct model in the scenario that was considered. It was simply to
show that the methods proposed in this paper are worth considering. More extensive
simulation studies would need to be completed in order to estimate the true proportions.
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Chapter 4
Comparison of Smoothing Splines
to Pop PK
4.1 Introduction
When predicted concentrations are the primary outcome of interest, rather than
pharmacokinetic parameters, one may consider using a mixed effects smoothing spline
model instead of a population pharmacokinetic model. This work is a comparison of
mixed effect smoothing splines to population pharmacokinetic models.
4.2 Methods
A comparison of mixed effect spline models to population PK models will be per-
formed. Simulations, with 400 replicates, each with 65 subjects, will be created for the
following scenarios.
1. Rich data, correctly specified model
2. Rich data, model misspecification of population PK model
3. Sparser data, correctly specified model
For each replicate, the following will be reported:
Mean squared error for all predictions: mean of
(yi − yˆi)2 (4.1)
We will look at standard errors across replicates to compare mixed effect spline
models to population PK models.
4.2.1 Traditional Population Pharmacokinetic Modeling
Population pharmacokinetic and pharmacodynamic (PK/PD) modeling is the char-
acterization of the distribution of probable PK/PD outcomes (parameters, concentra-
tions, responses, etc.) in a population of interest. These models consist of fixed and
random effects. The fixed effects describe the relationship between explanatory vari-
ables such as age, body weight, gender, and pharmacokinetic outcomes. The random
effects quantify unexplained variation in PK/PD outcomes.
Population PK models are hierarchical. There is a model for the individual, a
model for the population, and a model for the residual error. The individual model
consists of the curve of drug concentrations over time, a compartmental model. The
pharmacokinetic compartmental model is similar to a black box engineering model.
Each of the compartments is like a black box, where a system of differential equations
is derived based on the law of conservation of mass (Sandler, 1999).
The equations for the PK parameters represent the model for the population in
the hierarchy of models. The PK parameters are modeled with regression equations
containing fixed effects, covariates, and random effects (etas). The vector of random
effects (eta) is assumed to follow a multivariate normal distribution with mean 0 and
variance-covariance matrix Ω. Ω may be diagonal, full block, or block diagonal.
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The model for the residual error accounts for overall uncertainty in the concentra-
tions over time. The errors may weighted so that measurements with higher variability
are given less weight compared with measurements with smaller variability.
Hence, population pharmacokinetic models are non-linear mixed effects models.
The differential equations may or may not have a closed-form solution, and are solved
either analytically or numerically. The parameters are estimated using one of the
various algorithms available such as first order conditional estimation with interaction
(FOCEI). See (Wang, 2007) for a mathematical description of these algorithms.
4.2.2 Smoothing Splines
Suppose we are given a set of response variables {yi}ni=1 and predictor variables
{xi}ni=1 and we wish to estimate each yi based on f(xi), where f is a function that
minimizes
n∑
i=1
[yi − f(xi)]2 + λ
∫
{f ′′(t)}2 dt (4.2)
Any such f must be an element of the Sobolev space of functions with second derivatives
that are square integrable. The tuning parameter λ controls the tradeoff between
goodness of fit and smoothness. When λ = ∞, no second derivative is allowed for f ,
meaning that f must be linear and (4.2) reduces to the ordinary least squares criteria.
When λ = 0, then any f that interpolates the data will minimize (4.2).
It can be shown that (4.2) is minimized when f is a natural cubic spline with knots
at each xi (Hastie, Tibshirani and Friedman, 2008). Let x(1), x(2), . . . , x(n) be the order
statistics of the xi’s. Then a natural cubic spline f(x) with knots x1, x2, . . . , xn satisfies
the following properties:
1. f(x) is a a piecewise cubic polynomial. In particular, f(x) is a cubic polynomial
on [x(1), x(2)], [x(2), x(3)], . . . , [x(n−1), x(n)].
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2. f(x) and its first two derivatives are continuous on [x(1), x(n)].
3. f (j)(x(1)) = f
(j)(x(n)) = 0 for j = 2, 3. In other words, the second and third
derivatives of f are zero at the boundary knots, which implies that f is linear
outside the boundary knots.
See (Welham, 2009) or (Dierckx, 1995). For a complete description of smoothing splines
and methods for fitting spline models (including the choice of the tuning parameter λ),
see (Hastie, Tibshirani and Friedman, 2008).
4.3 Simulated Data Examples
For the simulations, two studies were created in Pharsight’s Trial Simulator. Both
studies had the same population PK model: a three compartment model with an IV
infusion of 20 mg/kg over 20 minutes (see Figure 4.1 for a graphical representation).
Figure 4.1: Simulated data
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Four hundred replicates of concentration-time data for sixty-five subjects was simu-
lated based on that model. The body weights were generated from a normal distribution
with a mean of 60 kg and a standard deviation of 15 kg.
The equations for the model are as follows.
dA1
dt
= In(t)− Cl · C − Cl2 · (C − C2)− Cl3 · (C − C3)
dA2
dt
= Cl2 · (C − C2)
dA3
dt
= Cl3 · (C − C3)
C = A1/V
C2 = A2/V 2
C3 = A3/V 3
where In(t) = Dose/T during infusion time T, and 0 otherwise
Dose = 20 mg/kg
T = 20 min
A constant CV percentage residual error model was generated with a CV percentage
of six percent.
CObs = C * (1 + CEps) where Var(CEps) = 0.0036
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The PK parameters were simulated with random effects on all the parameters.
V = 5.1 · exp(nV )
V 2 = 9.82 · exp(nV 2)
V 3 = 5.42 · exp(nV 3)
Cl = 2.6 · exp(nCl)
Cl2 = 2.05 · exp(nCl2)
Cl3 = 0.076 · exp(nCl3)
The random effects were assumed to be independent with means of zero and vari-
ances listed below.
V ar(nV ) = 0.01
V ar(nV 2) = 0.04
V ar(nV 3) = 0.013
V ar(nCl) = 0.06
V ar(nCl2) = 0.1
V ar(nCl3) = 0.1
The two studies differed only in the observation times (when samples were to be “col-
lected”). Observations were planned for a “rich data” case and a “sparse data” case.
For the “rich data” case, samples were to be collected at times (0, 1.5, 2, 2.5, 3, 3.5, 4,
5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 26, 27,
28, 29, 30, 32, 34, 36, 38, 40, 45, 50, 55, 60, 65, 70, 80, 90, 100, 110). For the ’sparse
data’ case, samples were to be collected at times (0, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10,
12, 14, 16, 24, 48).
After the data was simulated, models were fit using Phoenix NLME in command
line batch mode, with the FOCE L-B method. There were three cases for the model
fitting:
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1. Rich data, model correctly specified
2. Rich data, model misspecified (2 compartment instead of 3 compartment)
3. Sparse data, model correctly specified
4.4 Results
The 400 simulated ’Rich data, model correctly specified’ datasets each contained
3055 observations. The average MSE across the 400 replicates was 0.93 with a standard
deviation of 0.13 for the population PK models, while the average MSE (standard
deviation) was 2.26 (0.35) for the spline models.
The 400 simulated ’Rich data, model misspecified’ datasets each contained 3055
observations. The average MSE across the 400 replicates was 29.44 with a standard
deviation of 2.91.
The 400 simulated ’Sparse data, model correctly specified’ datasets each contained
975 observations. The average MSE across the 400 replicates was 2.71 with a standard
deviation of 0.40, while the average MSE (standard deviation) was 4.01 (0.73) for the
spline models.
4.5 Real Data Examples
Pharsights Phoenix NLME was used to fit models to the published indomethacin
dataset (Kwan et al., 1976). The indomethacin dataset, containing six subjects with
eleven observations each, was fit using a two-compartment IV bolus model with Clear-
ance parameterization and a proportional residual error model. Concentration units of
ug/mL were assumed, and a dose of 25000 ug at 0 hours was assumed. Random effects
were added to the PK parameters V, Cl, V2, and Cl2, in the form ThetaX*exp(nX),
where X is the parameter of interest.
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Table 4.1: Theta from final model of Indomethacin dataset
Parameter Estimate Units Stderr Stderr%
tvV 8898 mL 574.84 6.46
tvV2 19527.3 mL 3169.70 16.23
tvCl 7905.99 mL/h 608.53 7.70
tvCl2 5252.15 mL/h 768.93 14.64
stdev0 0.1440 0.02 13.25
stdev0 = estimated residual standard deviation
prefix of ’tv’ denotes fixed effect or typical value
Exploratory analysis (plot, Figure 4.2) showed two compartment PK. Individual
initial estimates were obtained using the curve stripping method (Gibaldi and Perrier,
1975) with a WinNonlin Classic model. The averages of the individual PK parameters
were used as initial estimates for the pop PK model.
Figure 4.2: Concentration versus time from Indomethacin dataset
The model appeared to fit well based on diagnostic plots (Figures 4.3, 4.4, 4.5).
The shrinkage was high for nV, but it was kept in. The relative standard errors for
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Table 4.2: Omega from final model of Indomethacin dataset
nV nCl nV2 nCl2
nV 0.0017
nCl 0 0.0338
nV2 0 0 0.0666
nCl2 0 0 0 0.1202
Shrinkage 0.7064 0.0329 0.3321 0.0727
the fixed effect parameter estimates were all well below 30. The value of the original
(Allen, 1974) PRESS statistic for the final model was 1.54, based on removal of 66 data
points, one at a time. The average of Allen’s PRESS over all data points was 0.02337.
4.6 Discussion
As expected, the pop PK models with the model misspecified had a higher MSE
on average than the pop PK models with the model correctly specified. The sparser
datasets with correctly specified models had significantly higher MSE on average than
the rich datasets with the same fitted models. Compared with the spline models, the
pop PK models tended to have lower MSE on average, however in the case where
the pop PK model was misspecified, a spline model would be far superior in terms of
prediction of concentrations.
In some cases, the data is too sparse to fit the correct structural pop PK model. For
example, plots of concentration versus time may appear to indicate a two compartment
model, but convergence fails when fitting a two compartment model while convergence
can be achieved with a one compartment model. In these cases one might consider a
spline model instead of a pop PK model if the primary outcome of interest is predicted
concentrations.
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Figure 4.3: Final model of Indomethacin dataset
Figure 4.4: Residuals from final model of Indomethacin dataset
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Figure 4.5: Observed versus predicted values from Indomethacin model
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Appendix
Results log from automated covariate selection of Remifentanil data
Base
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1071 0.0072 0.0291 0.2678 0.0490 0.1995
Rank 4.0000 1.0000 2.0000 6.0000 3.0000 5.0000
Base
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1144 0.0515 0.1558 0.3333 0.2700 0.3693
SE 0.0168 0.0096 0.0294 0.0716 0.0455 0.0664
Sum 0.1313 0.0611 0.1852 0.4050 0.3156 0.4357
dCldAGE
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1157 0.0271 0.1581 0.2779 0.2780 0.3366
SE 0.0164 0.0053 0.0293 0.0598 0.0463 0.0504
Sum 0.1321 0.0323 0.1875 0.3377 0.3243 0.3869 Add ClAge
dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1126 0.0403 0.1582 0.3220 0.2792 0.3599
SE 0.0163 0.0087 0.0295 0.0683 0.0467 0.0629
Sum 0.1290 0.0491 0.1877 0.3903 0.3259 0.4228
dCldMALE0
nV nCl nV2 nV3 nCl2 nCl3
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nPRESS 0.1152 0.0455 0.1582 0.2827 0.2733 0.3307
SE 0.0167 0.0090 0.0298 0.0618 0.0459 0.0513
Sum 0.1320 0.0544 0.1880 0.3445 0.3192 0.3820
dCldAGE
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1096 0.0142 0.0304 0.2743 0.0434 0.1905
Rank 4.0000 1.0000 2.0000 6.0000 3.0000 5.0000
dCldAGE
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1157 0.0271 0.1581 0.2779 0.2780 0.3366
SE 0.0164 0.0053 0.0293 0.0598 0.0463 0.0504
Sum 0.1321 0.0323 0.1875 0.3377 0.3243 0.3869
dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1207 0.0199 0.1563 0.2977 0.2712 0.3434
SE 0.0168 0.0043 0.0293 0.0642 0.0447 0.0511
Sum 0.1375 0.0242 0.1857 0.3619 0.3159 0.3945 Add ClBSA
dCldAGE dCldMALE0
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1167 0.0242 0.1563 0.2731 0.2752 0.3598
SE 0.0165 0.0048 0.0295 0.0618 0.0452 0.0538
Sum 0.1332 0.0290 0.1858 0.3349 0.3205 0.4135
dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1060 0.0174 0.0333 0.2705 0.0499 0.1515
Rank 4.0000 1.0000 2.0000 6.0000 3.0000 5.0000
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dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1207 0.0199 0.1563 0.2977 0.2712 0.3434
SE 0.0168 0.0043 0.0293 0.0642 0.0447 0.0511
Sum 0.1375 0.0242 0.1857 0.3619 0.3159 0.3945
dCldAGE dCldBSA dCldMALE0
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1197 0.0203 0.1548 0.2736 0.2739 0.3622
SE 0.0169 0.0044 0.0292 0.0627 0.0452 0.0540
Sum 0.1365 0.0247 0.1840 0.3363 0.3191 0.4162 Don’t add ClMale
dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1060 0.0174 0.0333 0.2705 0.0499 0.1515
Rank 4.0000 1.0000 2.0000 6.0000 3.0000 5.0000
dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1207 0.0199 0.1563 0.2977 0.2712 0.3434
SE 0.0168 0.0043 0.0293 0.0642 0.0447 0.0511
Sum 0.1375 0.0242 0.1857 0.3619 0.3159 0.3945
dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1175 0.0198 0.1105 0.3153 0.2866 0.3240
SE 0.0167 0.0043 0.0205 0.0631 0.0485 0.0479
Sum 0.1342 0.0241 0.1309 0.3784 0.3351 0.3719 Add V2Age
dV2dBSA dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
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nPRESS 0.1161 0.0198 0.1300 0.2683 0.2664 0.3325
SE 0.0165 0.0043 0.0268 0.0600 0.0440 0.0494
Sum 0.1326 0.0241 0.1569 0.3283 0.3104 0.3819
dV2dMALE0 dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1160 0.0198 0.1250 0.2983 0.2685 0.3080
SE 0.0166 0.0043 0.0236 0.0602 0.0442 0.0494
Sum 0.1326 0.0241 0.1486 0.3584 0.3127 0.3573
dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1072 0.0176 0.0457 0.2470 0.0342 0.1993
Rank 4.0000 1.0000 3.0000 6.0000 2.0000 5.0000
dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1175 0.0198 0.1105 0.3153 0.2866 0.3240
SE 0.0167 0.0043 0.0205 0.0631 0.0485 0.0479
Sum 0.1342 0.0241 0.1309 0.3784 0.3351 0.3719
dCl2dAGE dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1134 0.0193 0.0989 0.3370 0.1334 0.3636
SE 0.0158 0.0042 0.0192 0.0667 0.0225 0.0542
Sum 0.1292 0.0236 0.1182 0.4038 0.1559 0.4178 Add Cl2Age
dCl2dBSA dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1141 0.0197 0.1083 0.3345 0.2728 0.3016
SE 0.0162 0.0043 0.0201 0.0657 0.0454 0.0475
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Sum 0.1303 0.0239 0.1284 0.4002 0.3182 0.3490
dCl2dMALE0 dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1164 0.0196 0.1075 0.3056 0.2820 0.3509
SE 0.0167 0.0043 0.0205 0.0630 0.0460 0.0489
Sum 0.1331 0.0239 0.1280 0.3686 0.3280 0.3997
dCl2dAGE dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.0958 0.0104 0.0591 0.2808 0.0783 0.1616
Rank 4.0000 1.0000 2.0000 6.0000 3.0000 5.0000
dCl2dAGE dV2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1134 0.0193 0.0989 0.3370 0.1334 0.3636
SE 0.0158 0.0042 0.0192 0.0667 0.0225 0.0542
Sum 0.1292 0.0236 0.1182 0.4038 0.1559 0.4178
dV2dAGE dV2dBSA dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1081 0.0194 0.0870 0.2926 0.1344 0.3580
SE 0.0153 0.0042 0.0164 0.0625 0.0229 0.0518
Sum 0.1235 0.0236 0.1034 0.3552 0.1573 0.4098
dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1148 0.0194 0.0820 0.3061 0.1300 0.3321
SE 0.0157 0.0042 0.0153 0.0613 0.0220 0.0499
Sum 0.1305 0.0236 0.0973 0.3674 0.1520 0.3819 Add V2Male
dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
92
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.0975 0.0207 0.0771 0.2351 0.1026 0.2017
Rank 3.0000 1.0000 2.0000 6.0000 4.0000 5.0000
dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1148 0.0194 0.0820 0.3061 0.1300 0.3321
SE 0.0157 0.0042 0.0153 0.0613 0.0220 0.0499
Sum 0.1305 0.0236 0.0973 0.3674 0.1520 0.3819
dV2dAGE dV2dMALE0 dV2dBSA dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1080 0.0194 0.0827 0.2785 0.1301 0.3654
SE 0.0150 0.0042 0.0155 0.0616 0.0225 0.0512
Sum 0.1230 0.0236 0.0981 0.3401 0.1526 0.4166 Don’t add V2BSA
dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.0975 0.0207 0.0771 0.2351 0.1026 0.2017
Rank 3.0000 1.0000 2.0000 6.0000 4.0000 5.0000
dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.1148 0.0194 0.0820 0.3061 0.1300 0.3321
SE 0.0157 0.0042 0.0153 0.0613 0.0220 0.0499
Sum 0.1305 0.0236 0.0973 0.3674 0.1520 0.3819
dVdAGE dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0922 0.0194 0.0842 0.2858 0.1320 0.3087
SE 0.0151 0.0042 0.0153 0.0602 0.0225 0.0484
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Sum 0.1073 0.0236 0.0995 0.3460 0.1545 0.3572
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0498 0.0195 0.0854 0.3171 0.1356 0.3875
SE 0.0073 0.0043 0.0151 0.0653 0.0240 0.0724
Sum 0.0571 0.0237 0.1006 0.3824 0.1596 0.4599 Add VBSA
dVdMALE0 dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0631 0.0195 0.0835 0.3037 0.1453 0.3300
SE 0.0102 0.0043 0.0155 0.0633 0.0245 0.0504
Sum 0.0733 0.0237 0.0990 0.3670 0.1698 0.3804
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1690 0.0200 0.0553 0.3084 0.0808 0.1667
Rank 5.0000 1.0000 2.0000 6.0000 3.0000 4.0000
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0498 0.0195 0.0854 0.3171 0.1356 0.3875
SE 0.0073 0.0043 0.0151 0.0653 0.0240 0.0724
Sum 0.0571 0.0237 0.1006 0.3824 0.1596 0.4599
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCl2dBSA dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0511 0.0194 0.0835 0.2962 0.1357 0.3966
SE 0.0074 0.0043 0.0152 0.0622 0.0242 0.0725
Sum 0.0585 0.0237 0.0988 0.3584 0.1599 0.4691 Don’t add Cl2BSA
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCl2dMALE0 dCldAGE dCldBSA
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nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0515 0.0195 0.0846 0.2948 0.1354 0.3961
SE 0.0075 0.0043 0.0152 0.0617 0.0244 0.0733
Sum 0.0590 0.0238 0.0998 0.3565 0.1598 0.4694 Don’t add Cl2Male
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
Shrinkage 0.1690 0.0200 0.0553 0.3084 0.0808 0.1667
Rank 5.0000 1.0000 2.0000 6.0000 3.0000 4.0000
dVdBSA dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0498 0.0195 0.0854 0.3171 0.1356 0.3875
SE 0.0073 0.0043 0.0151 0.0653 0.0240 0.0724
Sum 0.0571 0.0237 0.1006 0.3824 0.1596 0.4599
dVdBSA dVdAGE dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0453 0.0193 0.0823 0.2937 0.1340 0.3892
SE 0.0070 0.0042 0.0151 0.0648 0.0236 0.0662
Sum 0.0523 0.0236 0.0974 0.3586 0.1577 0.4555 Don’t add VAge
dVdBSA dVdMALE0 dV2dAGE dV2dMALE0 dCl2dAGE dCldAGE dCldBSA
nV nCl nV2 nV3 nCl2 nCl3
nPRESS 0.0456 0.0194 0.0831 0.3019 0.1385 0.3795
SE 0.0067 0.0043 0.0152 0.0627 0.0246 0.0648
Sum 0.0523 0.0237 0.0983 0.3646 0.1632 0.4443 Don’t add VBSA
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